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Abstract: The novel 4-substituted 1,2,3-triazole L-ascorbic acid (L-ASA) conjugates with hydroxyethylene
spacer as well as their conformationally restricted 4,5-unsaturated analogues were synthesized as
potential antioxidant and antiproliferative agents. An evaluation of the antioxidant activity of novel
compounds showed that the majority of the 4,5-unsaturated L-ASA derivatives showed a better
antioxidant activity compared to their saturated counterparts. m-Hydroxyphenyl (7j), p-pentylphenyl
(7k) and 2-hydroxyethyl (7q) substituted 4,5-unsaturated 1,2,3-triazole L-ASA derivatives exhibited
very efficient and rapid (within 5 min) 2,2-diphenyl-1-picrylhydrazyl (DPPH•) radical scavenging
activity (7j, 7k: IC50 = 0.06 mM; 7q: IC50 = 0.07 mM). In vitro scavenging activity data were
supported by in silico quantum-chemical modelling. Thermodynamic parameters for hydrogen-atom
transfer and electron-transfer radical scavenging pathways of anions deprotonated at C2-OH or
C3-OH groups of L-ASA fragments were calculated. The structure activity analysis (SAR) through
principal component analysis indicated radical scavenging activity by the participation of OH group
with favorable reaction parameters: the C3-OH group of saturated C4-C5(OH) derivatives and the
C2-OH group of their unsaturated C4=C5 analogues. The antiproliferative evaluation showed that
p-bromophenyl (4e: IC50 = 6.72 µM) and p-pentylphenyl-substituted 1,2,3-triazole L-ASA conjugate
(4k: IC50 = 26.91 µM) had a selective cytotoxic effect on breast adenocarcinoma MCF-7 cells. Moreover,
compound 4e did not inhibit the growth of foreskin fibroblasts (IC50 > 100 µM). In MCF-7 cells treated
with 4e, a significant increase of hydroxylated hypoxia-inducible transcription factor 1 alpha (HIF-1α)
expression and decreased expression of nitric oxide synthase 2 (NOS2) were observed, suggesting
the involvement of 4e in the HIF-1α signaling pathway for its strong growth-inhibition effect on
MCF-7 cells.
Keywords: vitamin C; 1,2,3-triazole; antioxidant; quantum-chemical modelling; antitumor; HIF-1
1. Introduction
Biochemical processes in our body, including aerobic metabolism and inflammatory responses, as
well as exposure to the environment, result in the generation of unstable and highly reactive free radicals,
such as reactive oxygen (ROS) and nitrogen (RNS) species [1–4]. While ROS have an important biological
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role in cell signaling, homeostasis and defense against micro-organisms, an imbalance between ROS
production and ROS removal through the cell antioxidant protection system, comprised of endogenous
antioxidants, enzymes, dietary antioxidants, and metal-binding proteins, can induce oxidative stress
and various pathological conditions [2,5]. Free radicals may damage cellular components as they
react with membrane lipids, nucleic acids, proteins, carbohydrates, and other small molecules [6,7].
Increasing evidence indeed, suggests that many chronic diseases, such as cancer, cardiovascular diseases,
inflammation, neurodegenerative diseases, aging, diabetes, and atherosclerosis, are associated with
high levels of ROS [8,9].
Vitamin C (L-ascorbic acid, L-ASA) or more accurately the ascorbate anion (A, Figure 2), is an
excellent reducing agent and a powerful antioxidant co-factor required for key enzyme reactions [10–14].
Due to the low one electron reduction potential of the ascorbate radical (RA)/ascorbate (A) couple
(Figure 2), almost every oxidizing radical formed in the biological system, including the hydroxyl
(HO•), alkoxyl, peroxyl, thiol, and tocopheroxyl radicals cause one-electron oxidation of the ascorbate
anion, resulting in the formation of the resonance stabilized ascorbate radical which can be recycled
back to ascorbate [15,16]. Furthermore, structural modifications of hydroxyl groups of L-ASA by the
introduction of lipophilic moieties have led to L-ASA derivatives with improved radical scavenging
ability compared to L-ASA, especially in lipophilic parts of biological system [17–22]. While L-ASA
has an antioxidant property and protects the cell from damage caused by free radicals, when used
in pharmacological (millimolar) concentrations achieved through intravenous administration L-ASA
shows pro-oxidant activity [13,23–25]. The pro-oxidant activity can be explained by the ability of
ascorbate to reduce catalytic metals, for instance, Fe3+ to Fe2+, which than leads to the generation of the
superoxide anion, hydrogen peroxide and HO• by Fenton type reactions [26]. The higher concentration
of ROS in this case, may lead to a cancer cell’s death.
Recent findings showed that high levels of vitamin C selectively kill colorectal cancer cells with
KRAS and BRAF mutations by increasing ROS production, which blocks glucose metabolism and
subsequently causes the energy crisis and cell death [27,28]. Additionally, high-doses of vitamin C
showed a cytotoxic effect on breast adenocarcinoma (MCF7) and colon cancer (HT29) cells by inducing
metabolic changes, which caused insufficient ATP formation and cell death [29]. Additionally, high
concentrations of vitamin C showed cellular toxicity on proliferating neural stem/progenitor cells [30].
Furthermore, some lipophilic ASA derivatives with modified hydroxyl groups, as well as conjugates
of ASA with pyrimidine, purine, triazole and imidazole bases, exhibited antitumor and antiviral
activity [14].
Additionally, it was found that ascorbate decreases the activity of the hypoxia-inducible transcription
factor 1 (HIF-1) [31–34]. As a response to hypoxic stress, HIF-1 and HIF-2 are overexpressed in human
cancers, and upregulate the expression of genes involved in angiogenesis, glucose uptake, anaerobic
metabolism, and cell proliferation, making HIF an important target for cancer therapy [13,35–37].
Under normoxic conditions, the HIF-1α subunit is continually synthesized and then degraded in
the proteasome which requires HIF-hydroxylase enzymes to hydroxylate its proline and asparagine
residues. It is presumed that ascorbate decreases the HIF-1α protein levels by acting as a co-factor for
iron-dependent HIF-hydroxylase enzymes [38,39].
Encouraged by the observed antitumor effect of vitamin C and its derivatives, in our previous
work, we designed and synthesized 2,3-dibenzylated L-ASA derivatives and their C4=C5 unsaturated
analogues with a 1,4-disubstituted 1,2,3-triazole core on the C-6 atom of the lactone ring that exhibited
a pronounced and selective antitumoral and antiviral activity [40]. In continuation of our work and
with the aim to enhance the antioxidant activity of L-ASA, we have prepared a library of 1,2,3-triazole
L-ASA conjugates (Scheme 1) with free C-2 and C-3 hydroxyl groups, hypothesizing that diverse
substituted triazole moiety and hydroxyethylene and ethylidene linkers will have an impact on
free-radical-scavenging and antitumor properties.
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acid derivatives 1 and 5 with versatile terminal alkynes (2a, 2c–2h, 2j–2u) and 
6-(1,2,3-triazolyl)-6-deoxy (3a–3h, 3j–3u). Then, 6-(1,2,3-triazolyl)-4,5-didehydro-5,6-dideoxy-L-ASA 
(6c–6h, 6j–6g) derivatives were obtained [40].  
 
Scheme 1. Reagents and conditions: (i) Cu, 1 M copper(II) sulphate (CuSO4), tert-butanol, DMF, 
water, and a microwave reactor; (ii) 1 M boron trichloride (BCl3) and dry dichloromethane; (iii) 
copper(II) acetate (Cu(OAc)2) and methanol. 
The removal of the benzyl group was achieved via reaction of the 1,2,3-triazole L-ascorbic acid 
derivatives 3a–3h, 3j–3u, 6c–6h, and 6j–6q with boron trichloride (BCl3) in dry dichloromethane, 
affording compounds 4b–4q, 4i, 4k–4t, 4v, 7c–7g, and 7i–7q with yields from 42% to 86%.  
2.2. DPPH• Radical Scavenging Activity in Vitro 
Likewise, L-ASA, the 1,2,3-triazole L-ASA derivatives with free C2-OH and C3-OH groups were 
expected to be potent antioxidants. Therefore, they were tested as radical scavengers by reaction 
with the stable free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH•). The scavenging activity data are 
expressed as IC50 values and are summarized in Table 1. 
Table 1. The scavenging activity of L-ascorbic acid derivatives assessed by DPPH test. Results are 
presented as IC50 values (mM) of DPPH• inhibition after 5 and 10 min treatments. 
Scheme 1. Reagents and conditions: (i) Cu, 1 M copper(II) sulphate (CuSO4), tert-butanol, DMF, water,
and a microwave reactor; (ii) 1 M boron trichloride (BCl3) and dry dichloromethane; (iii) copper(II)
acetate (Cu(OAc)2) and methanol.
2. Results and Discussion
2.1. Synthe is
The target 1,2,3-triazole appended L-ASA derivatives were synthesized following Scheme 1.
The 1,2,3-triazole ring was introduced at the C-6 position of L-ascorbic acid via copper(I)-catalyzed
azide-alkyne (3 + 2) dipolar cycloaddition (CuAAC) [41] of the corresponding C-6 azido L-ascorbic acid
derivatives 1 and 5 wit versatile terminal alkynes (2a, 2c–2h, 2j–2u) and 6-(1,2,3-triazolyl)-6-deoxy
(3a–3h, 3j–3u). Then, 6-(1,2,3-tri zolyl)-4,5-didehydro-5,6-dideoxy-L-ASA (6c–6h, 6j–6g) deriv tives
ere obtained [40].
Th removal of the benzyl group was achieved via reaction of the 1,2,3-triazole L-ascorbic acid
derivatives 3a–3h, 3j–3u, 6c–6h, and 6j–6q with boron trichloride (BCl3) in dry dichloromethane,
affording compounds 4b–4q, 4i, 4k–4t, 4v, 7c–7g, and 7i–7q with yields from 42% to 86%.
2.2. DPPH• Radical Scavenging Activity in Vitro
Likewise, L-ASA, the 1,2,3-triazole L-ASA derivatives with free C2-OH and C3-OH groups were
expected to be potent antioxidants. Therefore, they were tested as radical scavengers by reaction
with the stable free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH•). The scavenging activity data are
expressed as IC50 values and are summarized in Table 1.
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Table 1. The scavenging activity of L-ascorbic acid derivatives assessed by DPPH test. Results are
presented as IC50 values (mM) of DPPH• inhibition after 5 and 10 min treatments.
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Comp. R IC50 (mM)a Comp. R IC50 (mM)a 
  Treatm. 5 
min 
Treatm.  
10 min 
  Treatm. 
5 min 
Treatm.  
10 min 
L-ASA 0.18 ± 0.06 0.17 ± 0.05 4t  
0.22 ± 
0.08 
0.12 ± 
0.02 
4b H 0.13 ± 0.05 
0.13 ± 
0.05 4v  
0.27 ± 
0.01 0.27 
4c 
 
0.26 ± 0.02 0.25 7c 
 
0.28 0.28 
4d 
 
0.27 ± 0.01 0.27 7d 
 
0.23 0.23 
4e  0.20 ± 0.01 
0.19 ± 
0.01 7e  0.28 0.28 
4f  0.20 ± 0.02 
0.14 ± 
0.01 7f  
0.10 ± 
0.02 
0.10 ± 
0.02 
4g  0.19 ± 0.01 
0.19 ± 
0.01 
7g  > 0.28 0.26 
4i 
 
>0.28 >0.28 7i 
 
0.10 ± 
0.05 
0.10 ± 
0.04 
4k  0.21 ± 0.07 
0.13 ± 
0.04 
7j 
 
0.06 0.06 
4l  0.17 ± 0.16 
0.16 ± 
0.14 7k  0.06 0.06 
4m  >0.28 >0.28 7l  
0.20 ± 
0.01 
0.20 
4n 
 
0.15 ± 0.06 0.10 ± 
0.03 
7m  0.20 0.19 
4o 
 
0.24 ± 
0.028 
0.24 ± 
0.04 
7n 
 
0.14 0.10 
4p  0.15 ± 0.06 
0.15 ± 
0.06 7o  
0.20 0.20 
4q  0.24 ± 0.02 0.23 7p  0.20 0.20 
4r 
 
0.25 
0.27 ± 
0.02 7q  0.07 0.07 
4s 
 
0.27 ± 0.02 0.25     
a IC50 —concentration of compound required to scavenge 50% of DPPH• free radicals. 
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Comp. R IC50 (mM)a Comp. R IC50 (mM)a 
  Treatm. 5 
min 
Treatm.  
10 min 
  Treatm. 
5 min 
Treatm.  
10 min 
L-ASA 0.18 ± 0.06 0.17 ± 0.05 4t  
0.22 ± 
0. 8 
0.12 ± 
0.02 
4b  0.13 ± 0.05 
0.13 ± 
0.05 4v  
0.27 ± 
0. 1 0.27 
4c 
 
0.26 ± 0.02 0.25 7c 
 
0.28 0.28 
4d 
 
0.27 ± 0.01 0.27 7d 
 
0.23 0.23 
4e  0.20 ± 0.01 
0.19 ± 
0.01 7e  0.28 0.28 
4f  0.20 ± 0.02 
0.14 ± 
0.01 7f  
0.10 ± 
0.02 
0.10 ± 
0.02 
4g  0.19 ± 0.01 
0.19 ± 
0.01 
7g  > 0.28 0.26 
4i 
 
>0.28 >0.28 7i 
 
0.10 ± 
0.05 
0.10 ± 
0.04 
4k  0.21 ± 0.07 
0.13 ± 
0.04 
7j 
 
0.06 0.06 
4l  0.17 ± 0.16 
0.16 ± 
0.14 7k  0.06 0.06 
4m  >0.28 >0.28 7l  
0.20 ± 
0.01 
0.20 
4n 
 
0.15 ± 0.06 0.10 ± 
0.03 
7m  0.20 0.19 
4o 
 
0.24 ± 
0.028 
0.24 ± 
0.04 
7n 
 
0.14 0.10 
4p  0.15 ± 0.06 
0.15 ± 
0.06 7o  
0.20 0.20 
4q  0.24 ± 0.02 0.23 7p  0.20 0.20 
4r 
 
0.25 
0.27 ± 
0.02 7q  0.07 0.07 
4s 
 
0.27 ± 0.02 0.25     
a IC50 —concentration of compound required to scavenge 50% of DPPH• free radicals. 
0.20 ± 0.01 0.19 ± 0.01 7e
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Comp. R IC50 (m )a Comp. R IC50 (m )a 
  Treatm. 5 
min 
Treatm.  
10 min 
  Treatm. 
5 min 
Treatm.  
10 min 
L- SA 0.18 ± 0.06 0.17 ± 0. 5 4t  
0.22 ± 
0.08 
0.12 ± 
.02 
4b H 0.13 ± 0.05 
0.13 ± 
0. 5 4v  
0.27 ± 
0.01 0.27 
4c 
 
0.26 ± 0.02 0.25 7c 
 
0.28 0.28 
4d 
 
0.27 ± 0.01 0.27 7d 
 
0.23 0.23 
4e  0.2  ± 0.01 
0.19 ± 
0.01 7e  0.28 0.28 
4f  0.2  ± 0.02 
0.14 ± 
0.01 7f  
0.10 ± 
0.02 
0.10 ± 
0.02 
4g  0.19 ± 0.01 
0.19 ± 
0.01 
7g  > 0.28 0.26 
4i 
 
>0.28 >0.28 7i 
 
0.10 ± 
0.05 
0.10 ± 
0.04 
4k  0.21 ± 0.07 
0.13 ± 
0.04 
7j 
 
0.06 0.06 
4l  0.17 ± 0.16 
0.16 ± 
0.14 7k  0.06 0.06 
4m  >0.28 >0.28 7l  
0.20 ± 
0.01 
0.20 
4n 
 
0.15 ± 0.06 0.10 ± 
0.03 
7m  0.20 0.19 
4o 
 
0.24 ± 
0.028 
0.24 ± 
0.04 
7n 
 
0.14 0.10 
4p  0.15 ± 0.06 
0.15 ± 
0.06 7o  
0.20 0.20 
4q  0.24 ± 0.02 0.23 7p  0.20 0.20 
4r 
 
0.25 
0.27 ± 
0.02 7q  0.07 0.07 
4s 
 
0.27 ± 0.02 0.25     
a IC50 — o centration f compound required to scav nge 50% of DPPH• f ee radicals. 
0.28 0.28
4f
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Comp. R IC50 (m )a Comp. R IC50 (m )a 
  Treatm. 5 
min 
Treatm.  
10 min 
  Treatm. 
5 min 
Treatm.  
10 min 
L-ASA 0.18 ± 0.06 0.17 ± 0.05 4t  
0.22 ± 
0.08 
0.12 ± 
0.02 
4b H 0.13 ± 0.05 
0.13 ± 
0.05 4v  
0.27 ± 
0.01 0.27 
4c 
 
0.26 ± 0.02 0.25 7c 
 
0.28 0.28 
4d 
 
0.27 ± 0.01 0.27 7d 
 
0.23 0.23 
4e  0.20 ± 0.01 
0.19 ± 
0.01 7e  0.28 0.28 
4f  0.20 ± 0.02 
0.14 ± 
0.01 7f  
0.10 ± 
0.02 
0.10 ± 
0.02 
4g  0.19 ± 0.01 
0.19 ± 
0.01 
7g  > 0.28 0.26 
4i 
 
>0.28 >0.28 7i 
 
0.10 ± 
0.05 
0.10 ± 
0.04 
4k  0.21 ± 0.07 
0.13 ± 
0.04 
7j 
 
0.06 0.06 
4l  0.17 ± 0.16 
0.16 ± 
0.14 7k  0.06 0.06 
4m  >0.28 >0.28 7l  
0.20 ± 
0.01 
0.20 
4n 
 
0.15 ± 0.06 0.10 ± 
0.03 
7m  0.20 0.19 
4o 
 
0.24 ± 
028 
0.24 ± 
0.04 
7n 
 
0.14 0.10 
4p  0.15 ± 0.06 
0.15 ± 
0.06 7o  
0.20 0.20 
4q  0.24 ± 0.02 0.23 7p  0.20 0.20 
4r 
 
0.25 
0.27 ± 
0.02 7q  0.07 0.07 
4s 
 
0.27 ± 0.02 0.25     
a IC50 —concentration of compound required to scavenge 50% of DPPH• free radicals. 
0.20 ± 0.02 0.14 ± 0.01 7f
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Comp. R IC50 (mM)a Comp. R IC50 (mM)a 
  Treatm.  
in
Treatm.  
10 in 
  Treatm. 
5 in 
Treatm.  
10 min 
L- SA 0.18 ± 0.06 0.17 ± .05 4t  
0.22 ± 
.08 
0.12 ± 
.0  
4b H 0.13 ± 0.05 
0.13 ± 
.05 4v  
0.27 ± 
.01 0.27 
4c 
 
0.26 ± 0.02 0.25 7c 
 
0.28 0.28 
4d 
 
0.27 ± 0.01 0.27 7d 
 
0.23 0.23 
4e  .2  ± 0.01 
0.19 ± 
.01 7e  0.28 0.28 
4f  .2  ± 0.02 
.14 ± 
.01 7f  
.10 ± 
.02 
.10 ± 
.02 
4g  0.19 ± 0.01 
.19 ± 
.01 
7g  > 0.28 0.26 
4i 
 
>0.28 >0.28 7i 
 
.10 ± 
.05 
.10 ± 
.04 
4k  0.21 ± 0.07 
0.13 ± 
.04 
7j 
 
0.06 0.06 
4l  0.17 ± 0.16 
0.16 ± 
. 4 7k  0.06 0.06 
4m  >0.28 >0.28 7l  
.20 ± 
.01 
.20 
4n 
 
0.15 ± 0.06 .10 ± 
.03 
7m  .20 0.19 
4o 
 
0.24 ± 
0.0 8 
0.24 ± 
.0  
7n 
 
0.14 .10 
4p  0.15 ± 0.06 
0.15 ± 
.06 7o  
.20 .20 
4q  0.24 ± 0.02 0.23 7p  .20 .20 
4r 
 
0.25 
0.27 ± 
.02 7q  0.07 0.07 
4s 
 
0.27 ± 0.02 0.25     
a IC50 — o centration f compound required to scav nge 50% of DPPH• f ee radicals. 
.10 ± 0.02 0.1 0.02
4g
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Comp. R IC50 (mM)a Comp. R IC50 (mM)a 
  Treatm. 5 
min 
Treatm.  
10 min 
  Treatm. 
5 min 
Treatm.  
10 min 
L-ASA 0.18 ± 0.06 0.17 ± 0.05 4t  
0.22 ± 
0.08 
0.12 ± 
0.02 
4b H 0.13 ± 0.05 
0.13 ± 
0.05 4v  
0.27 ± 
0.01 0.27 
4c 
 
0.26 ± 0.02 0.25 7c 
 
0.28 0.28 
4d 
 
0.27 ± 0.01 0.27 7d 
 
0.23 0.23 
4e  0.20 ± 0.01 
0.19 ± 
0.01 7e  0.28 0.28 
4f  0.20 ± 0.02 
0.14 ± 
0.01 7f  
0.10 ± 
0. 2 
0.10 ± 
0. 2 
4g  0.19 ± 0.01 
0.19 ± 
0.01 
7g  > 0.28 0.26 
4i 
 
>0.28 >0.28 7i 
 
0.10 ± 
0. 5 
0.10 ± 
0. 4 
4k  0.21 ± 0.07 
0.13 ± 
0.04 
7j 
 
0.06 0.06 
4l  0.17 ± 0.16 
0.16 ± 
0.14 7k  0.06 0.06 
4m  >0.28 >0.28 7l  
0.20 ± 
0. 1 
0.20 
4n 
 
0.15 ± 0.06 0.10 ± 
0. 3 
7m  0.20 0.19 
4o 
 
0.24 ± 
.028 
0.24 ± 
0.04 
7n 
 
0.14 0.10 
4p  0.15 ± 0.06 
0.15 ± 
0.06 7o  
0.20 0.20 
4q  0.24 ± 0.02 .23 7p  0.20 0.20 
4r 
 
0.25 
0.27 ± 
0.02 7q  0.07 0.07 
4s 
 
0.27 ± 0.02 0.25     
a IC50 —concentration of compound required to scavenge 50% of DPPH• free radicals. 
0.19 ± 0.01 0.19 ± 0.01 7g
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Comp. R IC50 (mM)a Comp. R IC50 (mM)a 
  Treatm. 5 
in 
Tre tm.  
10 in 
  Treatm.
5 in 
Tre tm.  
10 min 
L- SA 0.18 ± 0.06 0.17 ± 0.05 4t  
0.22 ± 
0.08 
0.12 ± 
0.02 
4b H 0.13 ± 0.05 
0.13 ± 
0.05 4v  
0.27 ± 
0.01 0.27 
4c 
 
0.26 ± 0.02 0.25 7c 
 
0.28 0.28 
4d 
 
0.27 ± 0.01 0.27 7d 
 
0.23 0.23 
4e  .2  ± 0.01 
0.19 ± 
0. 1 7e  0.28 0.28 
4f  .2  ± 0.02 
0.14 ± 
0.01 7f  
.10 ± 
0. 2 
.10 ± 
0. 2 
4g  0.19 ± 0.01 
0.19 ± 
0.01 
7g  > 0.28 0.26 
4i 
 
>0.28 >0.28 7i 
 
.10 ± 
0. 5 
.10 ± 
0. 4 
4k  0.21 ± 0.07 
0.13 ± 
0.04 
7j 
 
0.06 0.06 
4l  0.17 ± 0.16 
.16 ± 
0.14 7k  0.06 0.06 
4m  >0.28 >0.28 7l  
.20 ± 
0. 1 
.20 
4n 
 
0.15 ± 0.06 .10 ± 
0. 3 
7m  .20 0.19 
4o 
 
0.24 ± 
.028 
.24 ± 
0.04 
7n 
 
0.14 .10 
4p  0.15 ± 0.06 
.15 ±
0.06 7o  
.20 .20 
4q  0.24 ± 0.02 0.23 7p  .20 .20 
4r 
 
0.25 
0.27 ± 
0.02 7q  0.07 0.07 
4s 
 
0.27 ± 0.02 0.25     
a IC50 — o centrati n f compound required to scav nge 50% of DPPH• f ee radicals. 
> 0.28 0.26
4i
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Co p. R IC50 ( )a Co p. R IC50 ( )a 
  Treat . 5 
min 
Treat .  
10 min
  Treat . 
5 min 
Treat .  
10 in
L- S  0.18 ± 0.06 0.17 ± 0.05 4t  
0.22 ± 
0.08 
0.12 ± 
0.02 
4b  0.13 ± 0.05 
0.13 ± 
0.05 4v  
0.27 ± 
0.01 0.27 
4c 
 
0.26 ± 0.02 0.25 7c 
 
0.28 0.28 
4d 
 
0.27 ± 0.01 0.27 7d 
 
0.23 0.23 
4e  0.2  ± 0.01 
0.19 ± 
0.01 7e  0.28 0.28 
4f  0.2  ± 0.02 
0.14 ± 
0.01 7f  
0.10 ±
0. 2 
0.10 ±
0. 2 
4g  0.19 ± 0.01 
0.19 ± 
0.01 
7g  > 28 0.26 
4i 
 
>0.28 >0.28 7i 
 
0.10 ± 
0. 5 
0.10 ± 
0. 4 
4k  0.21 ± 0.07 
0.13 ± 
0.04 
7j 
 
0.06 0.06 
4l  0.17 ± 0.16 
0.16 ± 
0.14 7k  0.06 0.06 
4   >0.28 > 28 7l  
0.20 ±
0. 1 
0.20 
4n 
 
0.15 ± 0.06 0.10 ± 
0. 3 
7   0.20 0.19 
4o 
 
0.24 ± 
0.028
0.24 ± 
0.04 
7n 
 
0.14 0.10 
4p  0.15 ± 0.06 
0.15 ± 
0.06 7o  
0.20 0.20 
4q  0.24 ± 0.02 .23 7p  0.20 0.20 
4r 
 
0.25 
0.27 ±
0.02 7q  0.07 0.07 
4s 
 
0.27 ± 0.02 0.25     
a IC50 o centration f co pound required to scav nge 50% of DPPH• f ee radicals. 
.10 ± 0.05 0.10 0.04
4k
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Comp. R IC50 (mM)a Comp. R IC50 (mM)a 
  Treatm. 5 
min 
Tre tm.  
10 min 
  Treatm.
5 min 
Treatm.  
10 min 
L-ASA 0.18 ± 0.06 0.17 ± 0.05 4t  
0.22 ± 
0.08 
0.12 ± 
0.02 
4b H 0.13 ± 0.05 
0.13 ± 
0.05 4v  
0.27 ± 
0.01 0.27 
4c 
 
0.26 ± 0.02 0.25 7c 
 
0.28 0.28 
4d 
 
0.27 ± 0.01 0.27 7d 
 
0.23 0.23 
4e  0.20 ± 0.01 
0.19 ± 
0.01 7e  0.28 0.28 
4f  0.20 ± 0.02 
0.14 ± 
0.01 7f  
0.10 ± 
0. 2 
0.10 ± 
0. 2 
4g  0.19 ± 0.01 
0.19 ± 
0.01 
7g  > 0.28 .26 
4i 
 
>0.28 >0.28 7i 
 
0.10 ± 
0. 5 
0.10 ± 
0. 4 
4k  0.21 ± 0.07 
0.13 ± 
0.04 
7j 
 
0.06 0.06 
4l  0.17 ± 0.16 
0.16 ± 
0.14 7k  0.06 0.06 
4m  >0.28 >0.28 7l  
0.2  ± 
0. 1 
0.20 
4n 
 
0.15 ± 0.06 0.10 ±
0. 3 
7m  20 0.19 
4o 
 
0.24 ±
.028 
0.24 ± 
0.04 
7n 
 
0.14 0.10 
4p  0.15 ± 0.06 
0.15 ± 
0.06 7o  
0.20 0.20 
4q  0.24 ± 0.02 0.23 7p  0.20 0.20 
4r 
 
0.25 
0.27 ± 
0.02 7q  0.07 0.07 
4s 
 
0.27 ± 0.02 0.25     
a IC50 —concentration of compound required to scavenge 50% of DPPH• free radicals. 
0.21 ± 0.07 0.13 ± 0.04 7j
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Comp. R IC50 (mM)a Comp. R IC50 (mM)a 
  Treatm. 5 
in 
Treatm.  
10 in 
  Treat . 
5 in 
Treatm.  
10 min 
L- SA 0.18 ± 0.06 0.17 ± 0.05 4t  
0.22 ±
0.08 
0. 2 ± 
0.02 
4b H 0.13 ± 0.05 
0.13 ± 
0.05 4v  
0.27 ± 
0.01 0.27 
4c 
 
0.26 ± 0.02 0.25 7c 
 
0.28 0.28 
4d 
 
0.27 ± 0.01 0.27 7d 
 
0.23 0.23 
4e  .2  ± 0.01 
0.19 ± 
0.01 7e  0.28 0.28 
4f  .2  ± 0.02 
0.14 ± 
0.01 7f  
.10 ± 
0. 2 
.10 ± 
0. 2 
4g  0.19 ± 0.01 
0.19 ± 
0. 1 
7g  > 0. 8 26
4i 
 
>0.28 >0.28 7i 
 
.1  ± 
0. 5 
.10 ±
0. 4 
4k  0.21 ± 0.07 
0.13 ± 
0.04 
7j 
 
0.06 0.06 
4l  0.17 ± 0.16 
0.16 ± 
0.14 7k  0.06 0.06 
4m  >0.28 >0.28 7l  
0.2  ± 
0. 1 
.20 
4n 
 
0.15 ± 0.06 .10 ± 
0. 3 
7m  .20 0.19 
4o 
 
0.24 ± 
.028 
0.24 ± 
0.04 
7n 
 
0.14 .10 
4p  0.15 ± 0.06 
0.15 ± 
0.06 7o  
.20 .20 
4q  0.24 ± 0.02 23 7p  .20 .20 
4r 
 
0.25 
0.27 ± 
0.02 7q  0.07 0.07 
4s 
 
0.27 ± 0.02 0.25     
a IC50 — o centrati n f compound required to scav nge 50% of DPPH• f ee radicals. 
.06 0.06
4l
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Comp. R IC50 (m )a Comp. R IC50 (m )a 
  Treatm. 5 
min 
Treatm.  
10 min 
  Treatm. 
5 min 
Treatm.  
10 min 
L-ASA 0.18 ± 0.06 0.17 ± 0.05 4t  
0.22 ± 
0.08 
0.12 ± 
0.02 
4b H 0.13 ± 0.05 
0.13 ± 
0.05 4v  
0.27 ± 
0.01 0.27 
4c 
 
0.26 ± 0.02 0.25 7c 
 
0.28 0.28 
4d 
 
0.27 ± 0.01 0.27 7d 
 
0.23 0.23 
4e  0.20 ± 0.01 
0.19 ± 
0.01 7e  0.28 0.28 
4f  0.20 ± 0.02 
0.14 ± 
0.01 7f  
0.10 ± 
0. 2 
0.10 ± 
0. 2 
4g  0.19 ± 0.01 
0.19 ± 
0.01 
7g  > 0.28 .26 
4i 
 
>0.28 > .28 7i 
 
0.10 ± 
0. 5 
0.10 ± 
0. 4 
4k  0.21 ± 0.07 
0.13 ± 
0.04 
7j 
 
. 6 . 6 
4l  0.17 ± 0.16 
0.16 ± 
0.14 7k  0.06 0.06 
4m  >0.28 >0.28 7l  
0.2  ± 
0. 1 
0.20 
4n 
 
0.15 ± 0.06 0.10 ± 
0. 3 
7m  0.20 0.19 
4o 
 
0.24 ± 
.028 
0.24 ± 
0.04 
7n 
 
0.14 0.10 
4p  0.15 ± 0.06 
0.15 ± 
0.06 7o  
0.20 0.20 
q  .24  . 2 23 7p  .  .  
4r 
 
0.25 
0.27 ± 
0.02 7q  0.07 0.07 
4s 
 
0.27 ± 0.02 0.25     
a IC50 —concentration of compound required to scavenge 50% of DPPH• free radicals. 
0.17 ± 0.16 0.16 ± .14 7k
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o p.  I 50 ( )a o p.  I 50 ( )a 
  Treat . 5 
min 
Treat .  
10 min 
  Treat . 
5 min 
Treat .  
10 in 
L- S  0.18 ± 0.06 .17 ± 0.05 4t  
0.22 ±
0.08 
. 2 ± 
0.02 
4b  0.13 ± 0.05 
0.13 ±
0.05 4v  
0.27 ±
0.01 0.27 
4c 
 
0.26 ± 0.02 0.25 7c 
 
0.28 0.28 
4d 
 
0.27 ± 0.01 0.27 7d 
 
0.23 0.23 
4e  0.2  ± 0.01 
0.19 ± 
0.01 7e  0.28 0.28 
4f  0.2  ± 0.02 
0.14 ± 
0.01 7f  
0.10 ± 
0. 2 
0.10 ± 
0. 2 
4g  0.19 ± 0.01 
0.19 ± 
0.01 
7g  > 0. 8 26
4i 
 
>0.28 >0.28 7i 
 
0.10 ± 
0. 5 
0.10 ± 
0. 4 
4k  0.21 ± 0.07 
0.13 ± 
0.04 
7j 
 
0.06 0.06 
4l  0.17 ± 0.16 
0.16 ± 
0.14 7k  0.06 0.06 
4   >0.28 >0.28 7l  
0.20 ± 
0. 1 
0.2  
4n 
 
0.15 ± 0.06 0.10 ± 
0. 3 
7   20 0.19 
4o 
 
0.24 ± 
.028 
0.24 ± 
0.04 
7n 
 
0.14 0.10 
4p  0.15 ± 0.06 
0.15 ± 
0.06 7o  
0.20 0.20 
4q  0.24 ± 0.02 .23 7p  .20 .20 
4r 
 
0.25 
0.27 ± 
0.02 7q  0.07 0.07 
4s 
 
0.27 ± 0.02 0.25     
a IC50 o centration f co pound required to scav nge 50  of PP • f ee radicals. 
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L-ASA was used as contr l and its experim n lly assessed IC50 was 0.18 mM for the 5 min
treatment. The scavenging ac vity data showed that conju ates having a hydroxyethylene spacer
with a 4-substituted 1,2,3-triazole moiety at the C-6 position of L-ASA (4b−4v), in general, exhibited
activity similar to that of L-ASA. Compounds 4b, 4f, 4k, 4l, 4n, 4p, and 4t from the 6-(1,2,3-triazolyl)-
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6-deoxy-L-ASA and 7f, 7i−7k, 7n, and 7q from the 6-(1,2,3-triazolyl)-4,5-didehydro-5,6-dideoxy-L-ASA
series had higher antioxidant potencies in comparison with L-ASA. When a halogen (4c, 4d, or 4e)
and methoxy-substituted (4g) aryl moiety was introduced in the C-4 of 1,2,3-triazole, the antioxidant
activity was slightly lower (IC50 = 0.19–0.27 mM) in comparison with L-ASA and the unsubstituted
1,2,3-triazole L-ASA derivative 4b (IC50 = 0.13 mM at 5 and 10 min treatments). The introduction of
an alkyl in the para position of phenyl in compounds 4f and 4k, improved the antioxidant activity
after the 10 min treatment. Among 4-alkyl-substituted triazoles, cyclopropyl in 4l, decyl in 4n, and
3-chloropropyl substituents in 4p also improved the antioxidant activity compared to L-ASA. L-ASA
derivatives containing the benzenesulphonamide and dithiocarbamate moiety showed lower radical
scavenging activity after the 5 min treatment then L-ASA and the unsubstituted triazole 4b, but
benzenesulphonamide-substituted 1,2,3-triazole L-ASA derivative 4t had a better antioxidant activity
after the 10 min treatment then L-ASA and 4b, with an IC50 value of 0.12 mM.
It was observed that the majority of the 4,5-unsaturated L-ASA derivatives showed a better
antioxidant activity compared to their saturated counterparts (Figure 1). Interestingly, the introduction
of hydroxyl groups in 4,5-unsaturated L-ASA derivatives 7i, 7j, and 7q improved the radical scavenging
activities. Besides, the electron-donating p-methyl groups in 4f/7f, the p-pentyl-substituted aryl groups
in 4k/7k, and the long aliphatic chains in 4n/7n improved the antioxidant activity compared to L-ASA
as well.
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2.3. In Silico Analysis of Radical Scavenging Capacities
According to the pIC50 values, calculated as the negative logarithm of IC50 values (Table 1)—which
are within the range of 3.55−4.22 and have the pIC50 medians of 3.7, regardless the incubation time of
5 min or 10 min—the majority of L-ASA derivatives have similar DPPH• radical scavenging capacities.
The pIC50 value for the well-known antioxidant L-ASA was 3.75, demonstrating that most of compounds
have a similar or somewhat higher radical scavenging capacity compared to L-ASA.
For some pairs of L-ASA derivatives differing in the presence of C4-C5(OH) or C4=C5 fragments,
somewhat greater difference in their IC50 values has been observed (Table 1). For these pairs of
compounds—4b/7b, 4e/7e, 4g/7g, 4i/7i and 4q/7q—the extensive quantum-chemical calculations of
radical scavenging capacities were performed by using an approach widely exploited for the estimation
of the radical scavenging potential of polyphenols [42]. L-ASA is highly dissociated acidic molecule at
physiological pH of 7.4 (the negative logarithms of experimental acid dissociation constants (pKa) are
pKa,1 of 4.1 and pKa,2 of 11.4) [43].
The novel 1,2,3-triazole L-ASA conjugates were shown to be acidic molecules with similar pKa
values (Table 2). Accordingly, L-ASA reacts as a radical scavenger by donating an electron or a
hydrogen H-atom from its anion to a free radical (Figure 2). The first radical scavenging mechanism of
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L-ASA is described as a two-step sequential proton loss electron transfer (SPLET) process: after the
first step of deprotonation of the most acidic OH group (described by its acidity constant), an anion
(A) formed donates an electron with a capacity described by the electron transfer (free) energy (ETFE)
and changes into neutral radical (NR) (cyan path in Figure 2). However, an anion may also donate a
H-atom from the adjacent OH group through the hydrogen-atom transfer (HAT) mechanism which is
described by the O-H bond dissociation free energy (BDFE) parameter. The product of this radical
scavenging pathway is a radical anion (RA) which may release an additional electron and oxidize to a
diketo form of L-ASA known as dehydroascorbic acid (DHA, green path in Figure 2). However, the
neutral radical formed by SPLET, immediately releases a proton (pKaNR in Table 2) and converts to
a RA. Thus, both pathways have the same final dehydroascorbic acid product. The thermodynamic
preference of one of these two pathways has been estimated by comparison of reaction free energies of
underlying step processes (Table 2). The multivariate principal component analysis (PCA) analysis
in terms of the experimental pIC50 values and the calculated aqueous parameters ETFEA, BDFEA,
and ETFERA describing radical scavenging capacities of reducing anions and the intermediate radical
anion, explain 87.5% variance in the DPPH• activity of modelled compounds (Figure 3).
Table 2. Calculated aqueous reaction free energy parameters (kcal/mol): acid dissociation constant
of neutral specie (pKa) and its neutral radical (pKaNR), electron transfer free energies, and bond
dissociation free energy for an anion (ETFEA and BDFEA), and the ETFE of an intermediate radical
anion (ETFERA) (Figure 2) for C2-OH and C3-OH groups of selected compound pairs (saturated
C4-C5(OH) analogues from series 4 and unsaturated C4=C5 analogues from series 7).
Comp. Active OH pKa ETFEA pKaNR BDFEA ETFERA
L-ASA 2-OH 10.3 72.6 −6.3 57.3
3-OH 3.6 79.6 −4.4 66.9 76.6
L-ASA_C4=C5 a 2-OH 7.8 73.9 −4.4 61.3
3-OH 3.6 81.3 −5.6 66.9 77.9
4b 2-OH 10.4 72.7 −6.7 56.9
3-OH 3.7 79.3 −5.0 66.6 76.9
7b 2-OH 7.4 75.1 −5.0 61.6
3-OH 3.5 82.0 −5.8 67.0 79.0
4e 2-OH 10.4 71.0 −5.3 60.4
3-OH 3.5 82.0 −4.1 67.9 77.3
7e 2-OH 9.5 72.7 −4.2 60.4
3-OH 5.1 80.6 −5.4 66.5 79.7
4g 2-OH 10.2 79.8 −11.0 58.2
3-OH 3.4 79.2 −3.8 67.3 76.5
7g 2-OH 7.6 74.7 −4.6 61.8
3-OH 4.3 80.3 −5.4 66.3 78.3
4i 2-OH 10.4 72.5 −6.1 57.6
3-OH 3.3 79.8 −4.2 67.3 77.1
7i 2-OH 7.4 76.0 −5.1 62.3
3-OH 4.0 80.5 −5.0 66.9 78.1
4q 2-OH 10.7 72.8 −6.5 60.4
3-OH 2.4 82.3 −5.1 68.6 79.0
7q 2-OH 7.3 74.5 −4.2 62.0
3-OH 3.5 80.8 −5.1 67.1 78.0
a Not synthetized.
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Figure 2. Radical scavenging mechanisms and associated calculated aqueous free energies (bond
dissociation free energy (BDFE) and electron transfer free energy (ETFE) in kcal/mol) and negative
logarithm of acid dissociation constant for the most acidic OH group, pKa,1, Table 2), of L-ascorbic acid
(L-ASA) at physiological pH. The ascorbate anion deprotonated at the O-3 position may neutralize a free
radical by the donation of an H-atom (green pathway) or an electron (cyan pathway). The intermediate
radical anion transforms to the final product, dehydroascorbic acid (DHA), by further giving an electron.
The synthesized L-ASA derivatives may follow the same radical scavenging mechanisms.
The most significant difference between saturated C4-C5(OH) and unsaturated C4=C5 derivatives
is in acidity of the C2-OH group. While in saturated C4-C5(OH) L-ASA derivatives, the C3-OH group
is the only one deprotonated at pH 7.4, in derivatives with the C4=C5 bond, both C2-OH group and
C3-OH groups are acidic and may participate in the described DPPH• radical scavenging mechanisms
(Table 2). However, in the C4=C5 derivatives, intermediate C2-O– anion is generally characterized by
more favorable, lower ETFEA and BDFEA values than the C3-O– anion and it may be expected that
it is a primary reactive locus for scavenging of the DPPH• radical (Table 2). Thus, the best variance
explanation in the PCA analysis of DPPH• radical scavenging activity has been obtained by using the
more favorable parameter values for C3-OH groups of saturated C4-C5(OH) derivatives and for the
C2-OH group of the C4=C5 unsaturated derivatives, except for the compound 7e, for which C3-OH
parameters were used (Figure 3).
By comparing ETFEA, BDFEA, and ETFERA values for saturated and unsaturated analogues, all
three parameters are cl arly more favorable both groups C2-OH and C3-OH of 7q tha for the
C3-OH group of its satura ed analogue 4q, and it h s been observed as sign ficantly more active in
DPPH• ra i al scavenging, having a higher pIC50 value (Tables 1 and 2). ETFEA and BDFEA are also
more favorable for the stronger scavenger 7i in the 4i/7i pair. While BDFEA v lues for t 4e/7e pair
are comparable, the radical scavenging capacity of intermediate radical anion is somewhat better for 4e
than 7e, which may explain the somewhat higher pIC50 value of the saturated analogue 4e. However,
according to the calculation, unsaturated 7g should be a stronger scavenger than the saturated 4g,
which was not in agreement with the measured pIC50 values during 5 min and 10 min time periods
of incubation.
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Figure 3. Principal component analysis (PCA) biplot for derivatives containing C4C5(OH) (series 4)
or C4=C5 (series 7) fragments obtained by the PCA analysis performed in terms of the in vitro pIC50
values and three significant in silico radical scavenging parameters (Table 2). For saturated/unsaturated
derivatives, the more favorable parameter values for C3-O−/C2-O− anions have been used. The first
two principal components explain 87.5% variance in the data set. Coloring is according to the active
OH group in the 1st radical scavenging step. More active compounds have the higher pIC50 values and
are more on the right side of the plot.
2.4. Biological Evaluations
2.4.1. Antiprolifer tive Activities in Vitro
The C-6 substituted 1,2,3-triazole derivatives of L-ASA within the C5-OH group (4b−4q, 4i,
4k−4t, and 4v) and with the C4=C5 double bond (7c−7g and 7i−7q) were evaluated against seven
malignant tumor cell lines: lung adenocarcinoma (A549), ductal pancreatic adenocarcinoma (CFPAC-1),
colorectal carcinoma (HCT-116), cervical carcinoma (HeLa), hepatocellular carcinoma (HepG2), breast
adenocarcinoma (MCF-7), colorectal adenocarcinoma, and metastatic (SW620); as well as normal
cell lines: lung fibroblasts (WI-38) and foreskin fibroblasts (HFF-1) (Table 3, Table S1, Supplementary
Information). L-ASA was used as a positive control, and carboxyamidotriazole, a known antiproliferative
agent that inhibits tumor cell growth, invasion, and metastasis, and 5-fluorouracil (5-FU), were used as
reference compounds.
It can be observed that the majority of C-4 substituted 1,2,3-triazolyl-6-deoxy-L-ASA derivatives
were not cytotoxic. While compound 4e showed a selective antiproliferative effect on MCF-7 and A549
cells and 4k on MCF-7 cells, compounds 4d, 4o−4q, and 4v showed an only minor antiproliferative
effect at the highest tested concentrations (Table 1). However, except for 4e, 4q and 4v, other compounds
exhibited cytotoxicity on foreskin fibroblasts HFF-1 as well. The compounds showed themselves
to be more active than L-ASA, which showed no effects on the cell growth of the cells tested.
Carboxyamidotriazole, that contains a 1,2,3-triazole ring like the other tested compounds, showed a
non-selective, moderate antiproliferative effect on all evaluated cell lines.
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were not cytotoxic. hile compound 4e showed a selective antiproliferative effect on MCF-7 and 
A549 cells and 4k on MCF-7 cells, compounds 4d, 4o−4q, and 4v showed an only minor 
antiproliferative effect at the highest tested concentrations (Table 1). However, except for 4e, 4q and 
4v, other compounds exhibited cytotoxicity on foreskin fibroblasts HFF-1 as well. The compounds 
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cells tested. Carboxyamidotriazole, that contains a 1,2,3-triazole ring like the other tested 
compounds, showed a non-selective, moderate antiproliferative effect on all evaluated cell lines. 
The unsubstituted 1,2,3-triazolyl derivative 4b was not cytotoxic toward any of the tested cell 
lines, indicating that C-4 substitution at 1,2,3-triazole moiety has an impact on growth-inhibition. 
Among the aryl-substituted triazole derivatives, the fluoro and bromo-substituted aromatic moieties 
in 4d and 4e, respectively, had influences on the antiproliferative effect. hile 4d exhibited a 
81.65 75.82 64.79 56.76 95.34 39.81 92.04 >100 0.12 −0.94
4e
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Comp. R 
IC50 a (µM) 
clogPb 
A549 CFPAC-1 HCT-116 HeLa HepG2 MCF-7 SW620 WI-38 HFF-1 
4b H >100 >100 >100 >100 >100 >100 >100 >100 NA −2.89 
4c 
 
>100 >100 >100 >100 >100 >100 >100 >100 >100 0.56 
4d 
 
81.65 75.82 64.79 56.76 95.34 39.81 92.04 >100 0.12 −0.94 
4e Br
 
25.44 >100 >100 >100 >100 6.72 >100 73.93 >100 −0.42 
4f 
 
>100 >100 >100 >100 >100 >100 >100 >100 69.32 −0.80 
4g 
 
>100 >100 >100 >100 >100 >100 >100 >100 >100 −1.21 
4i 
 
>100 >100 >100 >100 >100 >100 >100 >100 0.92 −1.49 
4k 
 
>100 >100 >100 >100 >100 26.91 >100 >100 0.21 0.98 
4l 
 
>100 >100 >100 >100 >100 >100 >100 >100 4.61 −1.73 
4m  >100 >100 >100 >100 >100 >100 >100 >100 0.12 −1.17 
4n 
 
>100 >100 >100 >100 >100 >100 >100 >100 0.06 1.56 
4o 
 
>100 >100 >100 93.04 >100 >100 >100 94.95 <0.01 −1.26 
4p  >100 >100 >100 48.01 >100 99.59 >100 52.65 6.05 −1.39 
4q  >100 >100 63.34 >100 >100 >100 >100 >100 >100 −3.00 
4r 
 
>100 >100  >100 >100 >100 >100 >100 >100 −1.95 
4s 
 
>100 >100 >100 >100 >100 >100 >100 >100 0.40 −1.69 
4t 
 
>100 >100 >100 >100 >100 >100 >100 >100 >100 −1.59 
4v 
 
97.98 >100 >100 >100 >100 37.33 >100 >100 NA −2.40 
L-ASA >100 >100 >100 >100 >100 >100 >100 NA >100 −2.46 
Carboxyamidotriazole 51.61 41.55 19.88 31.84 40.09 14.69 41.33 / 32.61  
5-FU 2.80 0.14 / 8.81 9.04 0.096 0.08 0.94 /  
a Concentration of c mpounds required to inhibit human tumor cell lines and normal cell line 
growth by 50%; b values of n-octanol/water partition coefficients; clogP, were calculated by 
DataWarrior [44]. 
It can be observed that the majority of C-4 substituted 1,2,3-triazolyl-6-deoxy-L-ASA derivatives 
were not cytotoxic. While compound 4e showed a sele tive antiproliferative effect on MCF-7 and 
A549 cells and 4k on MCF-7 cells, compounds 4d, 4o−4q, and 4v showed n only minor 
antiproliferative eff ct at the highest tested concentrations (Table 1). However, ex ept for 4e, 4q and 
4v, other compounds exhi ited cytot xicity on foreskin fibrobl sts HFF-1 as well. The compounds 
showed the selves to be more active than L-ASA, which showed no effects on the cell growth of the 
cells tested. Carboxyamidotriazole, th t contains a 1,2,3-triazole ring like the other test d 
compounds, howed a on-selective, moderate antiproliferativ  effect on ll evaluated cell lines. 
The unsubstituted 1,2,3-triazolyl derivative 4b wa  not cyt t xic toward any of th  tested cell 
lines, indicating that C-4 substitution at 1,2,3-triazole moiety has an impact on growth-inhibition. 
Among the aryl-substituted triazole derivatives, the fluoro and bromo-substituted aromatic moieties 
in 4d and 4e, respectively, had influences on the antiproliferative effect. While 4d exhibited a 
25.44 >100 >100 >100 >100 6.72 100 73.93 >100 −0.42
4f
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>100 >100 >100 >100 >100 >100 >100 >100 0.92 −1.49 
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>100 >100 >100 >100 >100 26.91 >100 >100 0.21 0.98 
4l 
 
>100 >100  >100 >100 >100 >100 >100 4.61 −1.73 
4   >100 >100 >100 >100 >100 >100 >100 >100 0.12 −1.17 
4n 
 
>100 >100 >100 >100 >100 >100 >100 >100 0.06 1.56 
4o 
 
>100 >100  93.04 >100 >100 >100 94.95 <0.01 −1.26 
4p  >100 >100 >100 48.01 >100 99.59 >100 52.65 6.05 −1.39 
4q  >100 >100 63.34 >100 >100 >100 >100 >100 >100 −3.00 
4r 
 
>100 >100 >100 >100 >100 >100 >100 >100 >100 −1.95 
4s 
 
>100 >100  >100 >100 >100 >100 >100 0.40 −1.69 
4t 
 
>100 >100 >100 >100 >100 >100 >100 >100 >100 −1.59 
4v 
 
97.98 >100 >100 >100 >100 37.33 >100 >100 NA −2.40 
L-ASA >100 >100 >100 >100 >100 >100 >100 NA >100 −2.46 
Carboxya idotriazole 51.61 41.55 19.88 31.84 40.09 14.69 41.33 / 32.61  
5-FU 2.80 0.14 / 8.81 9.04 0.096 0.08 0.94 /  
a oncentration of c pounds required to inhibit hu an tu or cell lines and nor al cell line 
gro th by 50 ; b values of n-octanol/ ater partition coefficients; clogP, ere calculated by 
ata arrior [44]. 
It can be observe  that the ajority of -4 s bstit te  1,2,3-triaz lyl-6- eoxy-L- S  erivatives 
ere not cytotox c. hile co o n  4e sho e  a sele tive anti roliferative effect on F-7 an  
549 cells an  4  on F-7 cells, co o n s 4 , 4o−4 , an  4v sho e  n only inor 
anti roliferative eff ct at the highest teste  concentrations ( able 1). o ever, ex e t for 4e, 4  an  
4v, other co o n s exhibite  cytot x city on foreskin fibrobl sts FF-1 as ell. he co o n s 
sho e  the selves to be ore active than L- S , hich sho e  no effects on the ce l gro th of the 
cells teste . arboxya i o riazole, th t contains a 1,2,3-triazole ring l ke the other test  
co o n s, ho e  a on-selective, o erate anti roliferativ  effect on ll eval ate  cell lines. 
he ns bstit te  1,2,3-tr azolyl erivative 4  a  not cyt t xic to ar  any of the teste  cell 
lines, in icating that -4 s bstit tion at 1,2,3-triazole oiety has an act on gro th-inhibition. 
ong the aryl-s bstit te  triazole erivatives, the fl oro an  bro o-s bstit te  aro atic oieties 
in 4  an  4e, res ectively, ha  infl ences on the anti roliferative effect. hile 4  exhibite  a 
>100 >100 >100 >100 >100 >100 >100 >100 69.32 −0.80
4g
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81.65 75.82 64.79 56.76 95.34 39.81 92.04 >100 0.12 −0.94 
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4m  >100 >100 >100 >100 >100 >100 >100 >100 0.12 −1.17 
4n 
 
>100 >100 >100 >100 >100 >100 >100 >100 0.06 1.56 
4o 
 
>100 >100 >100 93.04 >100 >100 >100 94.95 <0.01 −1.26 
p  >100 48. 1 99.59 52.65 6.05 1 39
4q  >100 >100 63.34 >100 >100 >100 >100 >100 >100 −3.00 
4r 
 
>100 >100 >100 >100 >100 >100 >100 >100 >100 −1.95 
4s 
 
>100 >100 >100 >100 >100 >100 >100 >100 0.40 −1.69 
4t 
 
>100 >100  >100 >100 >100 >100 >100 >100 −1.59 
4v 
 
97.98 >100 > 00 >100 >100 37.33 >100 >100 NA −2.40 
L-ASA > 00 > 00 >100 > 00 >100 >100 > 00 NA >100 −2.46 
Carboxyamidotriazole 51.61 41.55 19.88 31.84 40.09 14.69 41.33 / 32.61  
5-FU 2.80 0.14 / 8.81 9.04 0.096 0.08 0.94 /  
a Concentration of compounds required to inhibit human tumor cell lines and normal cell line 
growth by 50%; b values of n-octanol/water partition coefficients; clogP, were calculated by 
DataWarrior [44]. 
It can be observed that the majority of C-4 substituted 1,2,3-triazolyl-6-deoxy-L-ASA derivatives 
were not cytotoxic. While compound 4e showed a selective antiproliferative effect on MCF-7 and 
A549 cells and 4k on MCF-7 cells, compounds 4d, 4o−4q, and 4v showed an only minor 
antiproliferative effect at the highest tested concentrations (Table 1). owever, except for 4e, 4q and 
4v, other co pounds exhibited cytotoxicity on foreskin fibroblasts HFF-1 as well. The compounds 
showed themselves to be more active than L-ASA, which showed no effects on the cell growth of the 
cells tested. Carboxyamidotriazole, that contains a 1,2,3-triazole ring like the other tested 
compounds, showed a non-selective, moderate antiproliferative effect on all evaluated cell lines. 
The unsubstituted 1,2,3-triazolyl derivative 4b was not cytotoxic toward any of the tested cell 
lines, indicating that C-4 substitution at 1,2,3-triazole moiety has an impact on growth-inhibition. 
Among the aryl-substituted triazole derivatives, the fluoro and bromo-substituted aromatic moieties 
in 4d and 4e, respectively, had influences on the antiproliferative effect. While 4d exhibited a 
>100 >100 >100 >100 >100 >100 100 >100 >100 −1.21
4i
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>100 >100 >100 >100 >100 26.91 >100 >100 0.21 0.98 
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4m  >100 >100 >100 >100 >100 >100 >100 >100 0.12 −1.17 
4n 
 
>100 >100 >100 >100 >100 >100 >100 >100 0.06 1.56 
4o 
 
>100 >100 >100 93.04 >100 >100 >100 94.95 <0.01 −1.26 
p   >100 48. 1  99.59  52.65 6. 5 1.39 
4q  >100 >100 63.34 >100 >100 >100 >100 >100 >100 −3.00 
4r 
 
>100 >100 >100 >100 >100 >100 >100 >100 >100 −1.95 
4s 
 
>100 >100 >100 >100 >100 >100 >100 >100 0.40 −1.69 
4t 
 
>100 >100 >100 >100 >100 >100 >100 >100 >100 −1.59 
4v 
 
97.98 >100 >100 >100 >100 37.33 >100 >100 NA −2.40 
L-ASA > 00 > 00 >100 > 00 >1 0 >100 > 00 NA >100 −2.46 
Carboxyamidotriazole 51.61 41.55 19.88 31.84 40.09 14.69 41.33 / 32.61  
5-FU 2.80 0.14 / 8.81 9.04 0.096 0.08 0.94 / 
a Concentration of compounds required to inhibit human tumor cell lines and normal cell line 
growth by 50%; b values of n-octanol/water partition coeffici nts; clogP, were calculated by 
Data a rior [44]. 
It can be observed that the ajority of C-4 substituted 1,2,3-triazolyl-6-deoxy-L-ASA derivatives
were not cytotoxic. hile co pound 4e showed a selective antiproliferative effect on CF-7 and
A549 cells and 4k on CF-7 cells, co pounds 4d, 4o−4q, and 4v showed an only inor
antiproliferative effect at the highest tested c centrations (Ta le 1). owever, except for 4e, 4q and
4v, other co pounds exhibited ytotoxicity on foreskin fibroblasts HFF-1 as well. The co pounds
showed the selves to be re ctive than L-ASA, which showed n  ffects on the cell growth of he
ells tested. Carboxya idotriazol , that contains a 1,2,3-triazole ring like the other tested 
co pounds, showed a non-selective, oder te antiproliferative effect on all ev luated c ll lin s.
The unsubstitu ed 1,2,3-triazolyl derivative 4b was not cytotoxic tow rd any of the tested cell
lines, indicating that C-4 substitution at 1,2,3-triazole iety has an i pac  on growth- nhib tion.
A ong the aryl-substituted tri zole derivatives, the fluoro and bro o-substituted aro atic oi ties
in 4d and 4e, respectively, had influences on the antiproliferative effect. hile 4d exhibited a 
>100 >100 >10 >100 >100 >10 >100 >100 0.92 −1.49
4k
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4 61 73
4   12 −1.17 
4n 
 
>100 >100 >100 >100 >100 >100 >100 >100 0.06 1.56 
4o 
 
>100 >100 >100 93.04 >100 >100 >100 94.95 <0.01 −1.26 
4p  >100 >100 >100 48.01 >100 99.59 >100 52.65 6.05 −1.39 
4q  >100 >100 63.34 >100 >100 >100 >100 >100 >100 −3.00 
4r 
 
>100 >100 >100 >100 >100 >100 >100 >100 >100 −1.95 
4s 
 
>100 >100 >100 >100 >100 >100 >100 >100 0.40 −1.69 
4t 
 
>100 >100 >100 >100 >100 >100 >100 >100 >100 −1.59 
4v 
 
97.98 >100 >100 >100 >100 37.33 >100 >100 NA −2.40 
L-ASA > 00 > 00 >100 > 00 >1 0 >100 > 00 NA >100 −2.46 
Carboxya idotriazole 51.61 41.55 19.88 31.84 40.09 14.69 41.33 / 32.61 
5-FU 2.80 0.14 / 8.81 9.04 0.096 0.08 0.94 /  
a oncentration of co pounds required to inhibit hu an tu or cell lines and nor al cell line
gro th by 50 ; b values of n-octanol/ ater partition coefficients; clogP, ere calculated by 
ataWarrior [44]. 
It can be observe  that the majority of -4 s bstit te  1,2,3-triazolyl-6- eoxy-L- S  erivatives 
ere not cytotoxic. While com o n  4e sho e  a selective anti roliferative effect on M F-7 an  
549 cells an  4  on M F-7 cells, com o n s 4 , 4o−4 , an  4v sho e  an only minor 
anti roliferative effect at the highest teste  c centrations ( a le 1). o ever, exce t for 4e, 4  an  
4v, other co o n s exhibite  ytotoxicity on foreskin fibroblasts FF-1 as ell. he com o n s 
sho e  themselves to be m re ctive than L- S , hich sho e  n  ffects on the cell gro th of he 
ells teste . arboxyami otriazol , that contains a 1,2,3-triazole ring like the other teste  
com o n s, sho e  a non-selective, mo er te anti roliferative effect on all ev l ate  c ll lin s. 
he ns bstit e  1,2,3-triazolyl erivative 4  as not cytotoxic to r  any of the teste  cell 
lines, in icating that -4 s bstit tion at 1,2,3-triazole m iety has an im ac  on gro th-inhibition. 
mong the aryl-s bstit te  tri zole erivatives, the fl oro an  bromo-s bstit te  aromatic moi ties 
in 4  an  4e, res ectively, ha  infl ences on the anti roliferative effect. While 4  exhibite  a 
>100 >100 >10 >100 >100 26.91 >100 >100 0.21 0.98
l
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Comp. R 
IC50 a (µM) 
clogPb 
549 CFP C-1 CT-116 eLa ep 2 MCF-7 SW620 WI-38 FF-1 
4b  >100 >100 >100 >100 >100 >100 >100 >100  −2.89 
4c 
 
>100 >100 >100 >100 >100 >100 >100 >100 >100 0.56 
4d 
 
81.65 75.82 64.79 56.76 95.34 39.81 92.04 >100 0.12 −0.94 
e Br
 
25.44 6.72 73.93 >100 42
f 
 
69.32 0 80
4g 
 
>100 >100 >100 >100 >100 >100 >100 >100 >100 −1.21 
4i 
 
>100 >100 >100 >100 >100 >100 >100 >100 0.92 −1.49 
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     26.91   0.2  0.98 
4l 
 
>100 >100 >100 >100 >100 >100 >100 >100 4.61 −1.73 
m    >100      .12 −1.17 
4n 
 
>100 >100 >100 >100 >100 >100 >100 >100 0.06 1.56 
o
 
93 4 >100 94 9 <0.01 26
p  >100 48. 1 99.59 52.65 6. 5 1 39
4q  >100 >100 63.34 >100 >100 >100 >100 >100 >100 −3.00 
4r 
 
>100 >100 >100 >100 >100 >100 >100 >100 >100 −1.95 
4s 
 
>100 >100 >100 >100 >100 >100 >100 >100 0.40 −1.69 
4t 
 
>100 >100 >100 >100 >100 >100 >100 >100 >100 −1.59 
4v 
 
97.98 >100 >100 >100 >100 37.33 >100 >100  −2.40 
L- S  > 00 > 00 >100 > 00 >1 0 >100 > 00  >100 −2.46 
Carboxyamidotriazole 51.61 41.55 19.88 31.84 40.09 14.69 41.33 / 32.61 
5-F  2.80 0.14 / 8.81 9.04 0.096 0.08 0.94 /  
a Concentration of com o n s req ire  to inhibit h man t mor cell lines an  normal cell line 
growth by 50%; b val es of n-octanol/water artition coefficients; clog , were calc late  by 
Data arrior [44]. 
It ca  e ser ed t at t e aj rit  f C-4 su stituted 1,2,3-triaz l l-6-de x -L-ASA deri ati es
were t c t t xic. ile c p u d 4e s wed a selecti e a tipr liferati e effect  C -7 a d
A549 cells a d 4k  C -7 cells, c p u ds 4d, 4 −4q, a d 4  s wed a  l i r
a tipr liferati e effect at t e i est tested c ce trati s (Ta le 1). we er, except f r 4e, 4q a d
4 , t er c p u ds ex i ited t t xicit   f res i  fi r lasts H -1 as well. T e c p u ds
s wed t e sel es t  e re cti e t a  L-ASA, w ic  s wed  ffects  t e cell r wt  f e
ells tested. Car x a id triaz l , t at c tai s a 1,2,3-triaz le ri  li e t e t er tested 
c p u ds, s wed a -selecti e, derate a tipr liferati e effect  all e luated c ll li s.
T e u su stitu ed 1,2,3-triaz l l deri ati e 4b was t c t t xic t w rd a  f t e tested cell
li es, i dicati  t at C-4 su stituti  at 1,2,3-triaz le iet  as a  i pac   r wt -i i ti .
A  t e ar l-su stituted tri z le deri ati es, t e flu r  a d r -su stituted ar atic i ties
i  4d a d 4e, respecti el , ad i flue ces  t e a tipr liferati e effect. ile 4d ex i ited a 
>100 >100 >10 >100 >100 >10 > 00 >100 4.61 −1.73
4m
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clogPb 
A549 CFPAC-1 HCT-116 HeLa HepG2 CF-7 S 620 I-38 HFF-1 
4b H >100 >100 >100 >100 >100 >100 >100 >100 NA −2.89 
4c 
 
>100 >100 >100 >100 >100 >100 >100 >100 >100 0.56 
4d 
 
81.65 75.82 64.79 56.76 95.34 39.81 92.04 >100 0.12 −0.94 
e Br
 
25.44     6.72  73.93 >100 .42 
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        69.32 0.8  
4g 
 
>100 >100 >100 >100 >100 >100 >100 >100 >100 −1.21 
4i 
 
>100 >100 >100 >100 >100 >100 >100 0.92 −1.49 
k 
 
26.91 0 2 0.98 
4l 
 
4 61 73
         .12 −1.17 
4n 
 
>100 >100 >100 >100 >100 >100 >100 >100 0.06 1.56 
o 
 
   93. 4  >100  94.9  <0.01 .26 
p >100 48.01 99.59 52.65 6. 5 1 39
q    63.34       3.00 
4r 
 
>100 >100 >100 >100 >100 >100 >100 >100 >100 −1.95 
4s 
 
>100 >100 >100 >100 >100 >100 >100 >100 0.40 −1.69 
4t 
 
>100 >100 >100 >100 >100 >100 >100 >100 >100 −1.59 
4v 
 
97.98 37.33 >10  NA 0
L-ASA >10  >100 >100 >100 >1 0 >100 >1 0 NA >100 −2.46 
Carboxya idotriazole 51.61 41.55 19.88 31.84 40.09 14.69 41.33 / 32.61  
5-FU 2.80 0.14 / 8.81 9.04 0.096 0.08 0.94 / 
a oncentration of co pounds required to inhibit hu an tu or cell ines and nor al cell line
gro th by 50 ; b values of n-octanol/ ater partition coefficients; clogP, ere calculated by 
at Warrior [44]. 
It can be observe  that the majority of -4 s bstit te  1,2,3- riazolyl-6- eoxy-L- S  erivatives
ere not cytotoxic. While com o n  4e sho e  a selective anti roliferative effect on M F-7 an
549 cells an 4  on M F-7 cells, com o n s 4 , 4o−4 , an  4v sho e  an only minor
anti roliferative effect at the highest teste  c centrat ons ( a le 1). o ever, exce t for 4e, 4  an
4v, other co o n s exhibite  ytotoxicity on foreskin fibroblasts FF-1 as ell. he com o n s
sho e  hemselves to be m re ctive than L- S , hich sho e  n  ffects on the cell gro th of he
ells teste . arboxyami otriazole, that contains a 1,2,3-triazole ring like the other teste  
com o n s, sho e  a non-selective, mo erate anti roliferative effect on all ev l ate  cell lin s. 
he ns bstit e  1,2,3-triazolyl erivative 4  as not cytotoxic to r  any f the teste  cell
lines, in icating that -4 s bstit tion at 1,2,3-triazo e m iety has an im ac  on gro th-inhib tion.
mong the aryl-s bstit te  tri zole erivatives, the fl oro an  bromo-s bstit te  aromatic moi ties
in 4  an  4e, res ectively, ha  infl ences on the anti roliferative effect. While 4  exhibite  a 
>100 >100 >10 >100 >100 >10 >100 >100 0.12 −1.17
4n
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a Conc nt ation of compounds equired o inhibit human tumor ce l lin s and normal cell line growth by 50%;
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The unsubsti u d 1,2,3-triaz lyl d rivative 4b w s n t cyt toxic toward a y of the tested cell
li es, indicating th t C-4 subs ituti n at 1,2,3-triazol moiety as a impact on growth-inhibition.
Am ng the aryl-substitu triazole deriv tives, t e fluor and bromo-substituted aromatic moieties in
4d an 4 , resp c ively, had nfluences on the ntiproliferative eff ct. Whil 4d xhibited a nonspecific
ytos atic effect, 4 displayed a s rong and selective antiproliferat v effect on breast adenocarcinoma
MCF-7 (IC50 = 6.72 µM) and mo ate activity o lung aden c cinoma A549 cells (IC50 = 25.44 µM).
ddition ll , compound 4e d not exhibit cyt t xi i y aga nst for skin fibroblas s HFF-1 (IC50 > 100
µM) a had ome cytotoxicity on fibroblasts WI-38 (IC50 = 73.93 µM; selec ivity index, SI = 11).
When comparing h activit es of ompounds 4e, 4f, nd 4g it can be conclud that the nature of
the substituent in the p-position of the phenyl has an influence on the antiproliferative effect. While
electron-withdrawing bromine in the structure of 4e increased the activity, compounds 4f and 4g
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with electron-donating groups on the 4-aryl-1,2,3-triazole units, did not show any cytotoxic effects.
The only exception to the observed impact of electron-donating groups on the inhibition effect was
p-pentylphenyl-1,2,3-triazolyl-6-deoxy-L-ASA derivative 4k that exerted a selective cytotoxic effect
on MCF-7 cells (IC50 = 26.91 µM), albeit, it showed cytotoxicity on foreskin fibroblasts (IC50 = 0.21 µM).
From the 4-alkyl substituted triazole derivatives, 4-tert-butyl in 4o, 3-chloropropyl in 4p, and
2-hydroxyethyl chains in 4g caused moderate to marginal cytostatic effects on cervical carcinoma
HeLa, colorectal carcinoma HCT-116, and breast adenocarcinoma MCF-7 cells. Compounds 4r−4t with
benzenesulphonamide substituents, did not show any cytotoxicity toward evaluated tumor cell lines.
The dithiocarbamate derivative 4v showed a selective but moderate antiproliferative effect toward
MCF-7 cells (IC50 = 37.33 µM). Referring to the lipophilicity of the newly synthesized compounds, their
clogP values are within the range of −3.00–2.67 (Table 3 and Table S1, Supplementary Information).
Compounds 4e and 4k with the best inhibitory activity and clogP values of −0.42 and 0.98, respectively,
showed themselves to be more lipophilic than L-ASA (clogP = −2.46).
The C-6 substituted 1,2,3-triazole 4,5-unsaturated L-ASA derivatives (7c−7g and 7i−7q) showed
no antiproliferative effect on the tested cell panel at concentrations lower than 100 µM (Table S1,
Supplementary Information), which implies that the linker connecting the lactone ring and the
1,2,3-triazole moiety has an influence on the antitumor activity of tested compounds, which is in
accordance with the previously shown antitumor effects of 2,3-O,O-dibenzylated L-ASA derivatives [40].
2.4.2. The Detection of Apoptosis and the Validation of HIF-1α and NOS2 Protein Targets for 4e
In order to examine whether the antitumor effect of p-bromophenyl-substituted L-ASA derivative
4e, which showed a selective antiproliferative effect on MCF-7 tumor cell line, can be connected to the
induction of apoptosis or any other kind of cell death, an Annexin V assay was performed following a
procedure described previously [45].
The results obtained indicate that compound 4e induced apoptosis in MCF-7, and showed a
moderate increase in early apoptotic cell populations of 12.4% and late apoptotic cell populations, 2.0%,
after 24 h-treatment at concentration 1 × IC50 (Table 4). After 48 h the cell death rate in the treated
cells was similar to the untreated MCF-7 control cells for the higher tested concentration, while the
percentage of cells in early apoptosis was higher by 35.2%, in treated cells at concentration 1 × IC50,
compared with untreated cells.
Table 4. Results of the Annexin V assay a.
Cell Line Duration ofTreatment
Comp.
Concentration
Early
Apoptosis (%)
Late Apoptosis
(%)
Necrosis
(%)
MCF-7
24 h
Control 18.2 4.4 0
4e (6.72 µM) 30.6 6.4 0.8
4e (13.44 µM) 5.3 38.1 15.9
48 h
Control 11.4 10.6 0
4e (6.72 µM) 46.6 4.2 0.8
4e (13.44 µM) 9.1 2.3 0
a Results are presented as percentages of early apoptotic cells, late apoptotic/primary necrotic cells, and necrotic
cells after 24 h and 48 h treatment. Cells were treated with 4e at 6.72 µM (1 × IC50) and at 13.44 µM (2 × IC50).
Control—untreated MCF-7 cells.
To further understand the observed antiproliferative and cell death effects on MCF-7 cells by
p-bromophenyl 1,2,3-triazole L-ASA conjugate 4e, the analysis of the relative expressions of Hypoxia-
inducible factor I alpha (HIF-1α) and Nitric oxide synthase 2 (NOS2, iNOS) protein, as potential
targets of 4e, was performed by western blot (Figure 4). The results showed that in MCF-7 cells treated
with 4e for 48 h, a statistically significant increase of hydroxylated HIF-1α (Pro564) expression was
observed. Increased levels of hydroxylated HIF-1α (Pro564) would imply an increased form of HIF-1α
for proteasomal degradation. Furthermore, 48 h after incubation of MCF-7 cells with 4e, a decreased
expression of NOS2 was observed.
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Figure 4. Western blot analysis of predicted protein targets of compounds 4e. Representative western
blots are shown on the left panel, where cellular levels of selected proteins before and after treatment of
MCF-7 cells with compound 4e, at IC50 = 6.72 µM for 24 and 48 h, can be observed. C denotes control
(untreated) cells. Approximate molecular weights (kDa) of target proteins are presented. Relative
signal intensities of target proteins were normalized to the alpha-tubulin loading control and are shown
in the right panel. Data are presented as mean values± SDs. Statistically significant (p < 0.5) differences
in the expression levels are marked by an asterisk (*).
NOS2s are homodimer enzymes that catalyze the formation of nitric oxide radicals (NO) from
L-arginine and oxygen. NO is an important signaling molecule and mediates various physiological
and pathological pr cess s, including systemic blood p essur , the upregulation of hypoxic genes,
the regulatio of stres response pathways, host–microbe interactions, immune sign ing,
apopt sis [46–48]. The majority of reports indicate that NO in uces HIF-1α accumulation but the
molecular mechanisms of the regulation of HIF-1α activity by NO are not yet defined and are dependent
on conditions being hypoxic or normoxic, and on the concentration of NO [47–53]. Additionally, it
was reported that vitamin C reduces the NO-induced stabilization of HIF-1α in endothelial cells from
umbilical cords (HUVECs) under normoxic conditions [54].
Based on the literature overview, we can conclude that the decreased expression of NOS2 is
consistent with the enhanced expression of hydroxylated HIF-1α and the antiproliferative effects of 4e
on MCF-7 observed.
2.4.3. Cell Metabolism Analysis—Mitochondrial Toxicity
The effects on the mitochondrial respiration after 24 h exposure of MCF-7 and HFF-1 cells to L-ASA
and 4e tested at concentrations comparable to the DPPH test (IC50 values and correspondingly higher or
lower concentrations) were assessed by use of the Seahorse XF Cell Mito Stress Test kit (Figure 5). Even
though no statistically relevant changes were observed, interesting trends were consistent. The basal
respiration and ATP production of MCF-7 and HFF-1 cells after sequential injection of the standard assay
compounds, as described in the Material and methods section, was affected by higher concentrations
of L-ASA and compound 4e that both induced a decrease in the cellular-metabolism rate. A lower
L-ASA concentration (50 mM) did not act on the mitochondrial activity (dashed lines in Figure 5,
panel A). In MCF-7 tumor cells, it was clearly visible that higher L-ASA concentrations decreased the
basal cell respiration and ATP production in the way that the whole cell metabolism switched towards
non-mitochondrial respiration while this effect was not observed in the normal HFF-1 fibroblasts.
Compound 4e increased the basal respiration and ATP production of MCF-7 cells at its IC50 concentration
(6.72 µM) and 2 × IC50 concentration (13.44 µM), while it lowered cellular mitochondrial metabolism,
switching it towards protein leaking at the lower tested concentration (3.36 µM). Compound 4e did not
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affect the basal cell respiration or ATP production of HFF-1 cells which correlates with MTT-results
where 4e showed no cytotoxicity on this cell line at micromolar concentrations (Table 3; IC50 > 100 µM).
Interestingly, 4e showed a slightly positive effect on the cellular metabolism and mitochondrial activity
of HFF-1 at a concentration of 100 µM (Figure 5, panel B). The observed differences in compound
4e activity on MCF-7 tumor cells in comparison with normal fibroblasts HFF-1 may be due to the
specific metabolic status of tumor cells, in which case an antioxidant compound with ROS scavenging
properties, such as L-ASA, may have a cytotoxic effect; i.e., through a pro-oxidant effect on cancer cells
associated with increase of ROS in tumor cells [55]. Particularly in MCF-7 cells, a small amount of an
important cellular antioxidant enzyme manganese-dependent superoxide dismutase (MnSOD) was
found in comparison with other cell lines [56]. It is therefore, possible that the compound 4e exerts
a pro-oxidant activity in MCF-7 cells, which elevates the levels of ROS and induces cell death. This
hypothesis should be further studied, however, in more experimental detail.
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with compound 4e having a p-bromophenyl substituent at C-4 of triazole. *The zero (0) on the X axis
denotes the starting point of measurment upon addition of oligomycine, mitochondrial oxidative
phosphorylation uncoupler carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP), and
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3. Materials and Methods
3.1. Chemistry
3.1.1. General
The elting i t f novel compounds wer det rmined using a Kofler micro hot-stage (R ichert,
Wien, Austria) apparatus. The progress of all reactions was m itored by thin-layer chromatography
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(TLC) on silica gel 60F-254 plates (Merck, Darmstadt, Germany) and the spots were observed under
UV light (254 nm). Purification of compounds using column chromatography was carried out with
silica gel (0.063–0.2 mm) (Fluka, Buchs, Switzerland). All 1H and 13C NMR spectra were recorded
in DMSO-d6 at 298 K on a Bruker 300 or 600 MHz NMR spectrometer (Bruker Biospin, Rheinstetten,
Germany). Chemical shifts were referenced to the signal of DMSO at δ: 2.50 ppm (1H NMR) and δ:
39.50 ppm (13C NMR). High-resolution mass spectra (HRMS) of the final compounds were recorded
on a 4800 Plus MALDI TOF/TOF mass spectrometar (Applied Biosystems, Foster City, CA, USA).
Acquisitions were performed in positive ion reflectron mode.
3.1.2. Preparation of Compounds
General procedure for the removal of the benzyl groups: 1,2,3-triazole-L-ascorbic acid derivatives
3a−3h, 3j−3u, 6c−6h, and 6j−6q were dried using a vacuum pump. Dry dichloromethane (around
20 mL) was added to the compound under an argon atmosphere. The reaction mixture was cooled to
−65 ◦C and 1 M boron trichloride solution (BCl3, 6 equivalents) was added dropwise to the reaction
mixture. The reaction mixture was stirred for 3 h at −65 ◦C and was left in the freezer overnight.
A mixture of dichloromethane and methanol (10 mL) was then added and the reaction mixture was
stirred for 30 min at room temperature. The solvent was evaporated and Amberlite IRA 743 was added
to neutralize the reaction mixture. The reaction mixture was filtered and the solvent was evaporated.
The compounds were purified using a very short column filled with silica (CH2CH2:MeOH = 100:1; 50:1;
10:1). After trituration of the obtained product with n-hexane, diethyl ether, dichloromethane, acetone,
and methanol, compounds 4b–4q, 4i, 4k–4t, 4v, 7c−7g, and 7i−7q were isolated as white powders.
The preparation of 6-deoxy-6-(1,2,3-triazol-1-yl)-L-ascorbic acid (4b): Compound 4b (61.8 mg; 57%; m.p. =
219–221 ◦C) was synthesized according to the general procedure using compound 3a (194.9 mg; 0.478
mmol); 1 M BCl3 (2.9 mL) and CH2Cl2 (20 mL). 1H NMR (600 MHz, DMSO) δ: 11.12 (bs, 1H, OH), 8.43
(bs, 1H, OH), 8.10 (s, 1H, H-8), 7.72 (s, 1H, H-7), 5.45 (bs, 1H, OH), 4.71 (d, J = 1.4 Hz, 1H, H-4), 4.65
(dd, J = 13.8 Hz, 3.9 Hz, 1H, H-6), 4.41 (dd, J = 13.8 Hz, 9.3 Hz, 1H, H-6), 4.19 (d, J = 6.4 Hz, 1H, H-5)
ppm. 13C NMR (151 MHz, DMSO) δ: 170.3 (C-1), 152.0 (C-3), 133.0 (C-8), 125.8 (C-7), 118.3 (C-2), 75.6
(C-4), 67.2 (C-5), 52.4 (C-6) ppm. HRMS (ESI Q-TOF): calculated for C8H9N3O5 [M + H]+ = 228.0620;
found = 228.0626.
Preparation of 6-deoxy-6-[4-(3,5-bis(trifluoromethyl)phenyl)-1,2,3-triazol-1-yl]-L-ascorbic acid (4c): Compound
4c (119.0 mg; 86%; m.p. ≥ 250 ◦C) was synthesized according to the general procedure using compound
3c (194.5 mg; 0.314 mmol); 1 M BCl3 (1.9 mL) and CH2Cl2 (20 mL). 1H NMR (600 MHz, DMSO) δ:
11.18 (s, 1H, OH), 8.99 (s, 1H, H-7), 8.53 (s, 2H, Ph-2, Ph-6), 8.46 (s, 1H, OH), 8.07 (s, 1H, Ph-4), 5.60
(d, J = 6.9 Hz, 1H, OH), 4.79 (d, J = 1.6 Hz, 1 H, H-4), 4.74 (dd, J = 13.8 Hz, 4.0 Hz, 1H, H-6), 4.46 (dd,
J = 13.9 Hz, 9.3 Hz, 1H, H-6), 4.29–4.23 (m, 1H, H-5) ppm. 13C NMR (151 MHz, DMSO) δ: 170.2 (C-1),
151.9 (C-3), 143.4 (C-8), 133.4 (Ph-1), 131.4; 131.1; 130.9; 130.7 (q, 2JCF = 32.9 Hz, Ph-3, Ph-5), 126.0; 124.1;
122.3; 120.5 (q, 1JCF = 272.8 Hz), 125.3 (Ph), 124.5 (Ph), 121.0 (C-7), 118.3 (C-2), 75.4 (C-4), 67.0 (C-5), 53.1
(C-6) ppm. HRMS (ESI Q-TOF): calculated for C16H11F6N3O5 [M + H]+ = 440.0681; found = 440.0671.
Preparation of 6-deoxy-6-[4-(3,5-difluorophenyl)-1,2,3-triazol-1-yl]-L-ascorbic acid (4d): Compound 4d (44.4
mg; 46%; m.p. = 189–191 ◦C) was synthesized according to the general procedure using compound
3d (148.6 mg; 0.286 mmol); 1 M BCl3 (1.7 mL) and CH2Cl2 (20 mL). 1H NMR (600 MHz, DMSO) δ:
11.16 (s, 1H, OH), 8.72 (s, 1H, H-7), 8.45 (s, 1H, OH), 7.59–7.56 (m, 2H, Ph-2, Ph-6), 7.35–7.10 (m, 1H,
Ph-4), 5.57 (s, 1H, OH), 4.78 (d, J = 1.5 Hz, 1H, H-4), 4.71 (dd, J = 13.8 Hz, 3.8 Hz, 1H, H-6), 4.42 (dd,
J = 13.8 Hz, 9.4 Hz, 1H, H-6), 4.26–4.22 (m, 1H, H-5) ppm. 13C NMR (151 MHz, DMSO) δ: 170.2 (C-1),
163.7; 163.6; 162.1; 162.0 (dd, 1JCF = 245.6 Hz, 3JCF = 13.7 Hz, Ph-3, Ph-5), 151.9 (C-3), 144.1 (C-8), 134.4;
134.3; 134.3 (t, 3JCF = 10.7 Hz, Ph-1), 123.9 (C-7), 118.3 (C-2), 108.3–107.7 (m, Ph-2, Ph-6), 103.1; 103.0;
102.8 (t, 2JCF = 25.9 Hz, Ph-4), 75.5 (C-4), 67.0 (C-5), 53.0 (C-6) ppm. HRMS (ESI Q-TOF): calculated for
C14H11F2N3O5 [M + H]+ = 340.0745; found = 340.0750.
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Preparation of 6-[4-(4-bromophenyl)-1,2,3-triazol-1-yl]-6-deoxy-L-ascorbic acid (4e): Compound 4e (111.7 mg;
61%; m.p. = 159–160 ◦C) was synthesized according to the general procedure using compound 3e
(268.5 mg; 0.477 mmol); 1 M BCl3 (2.86 mL) and CH2Cl2 (20 mL). 1H NMR (300 MHz, DMSO) δ: 11.10
(s, 1H, OH), 8.62 (s, 1H, H-7), 8.48 (bs, 1H, OH), 7.81 (d, J = 8.5 Hz, 2H, Ph), 7.65 (d, J = 8.5 Hz, 2H, Ph),
5.55 (s, 1H, OH), 4.77 (d, J = 1.2 Hz, 1H, H-4), 4.69 (dd, J = 13.7 Hz, 3.7 Hz, 1H H-6), 4.42 (dd, J = 13.7 Hz,
9.3 Hz, 1H, H-6), 4.30–4.18 (m, 1H, H-5). 13C NMR (151 MHz, DMSO) δ: 170.2 (C-1), 157.3 (C-3), 145.0
(C-8), 131.8 (Ph), 130.1 (Ph-q), 127.0 (Ph), 122.8 (C-7), 120.7 (Ph-q), 118.2 (C-2), 75.5 (C-4), 67.1 (C-5), 52.9
(C-6) ppm. HRMS (ESI Q-TOF): calculated for C14H12BrN3O5 [M + H]+ = 382.0039; found = 382.0023.
Preparation of 6-deoxy-6-[4-tolyl-1,2,3-triazol-1-yl]-L-ascorbic acid (4f): Compound 4f (42.0 mg; 42%; m.p.
= 152–154 ◦C) was synthesized according to the general procedure using compound 3f (156.6 mg; 0.315
mmol); 1 M BCl3 (1.9 mL); CH2Cl2 (20 mL). 1H NMR (300 MHz, DMSO) δ: 11.17 (bs, 1H, OH), 8.50 (s,
1H, H-7), 8.46 (bs, 1H, OH), 7.73 (d, J = 8.0 Hz, 2H, Ph), 7.25 (d, J = 8.0 Hz, 2H, Ph), 5.54 (d, J = 6.7 Hz,
1H, OH), 4.77 (d, J = 1.0 Hz, 1H, H-4), 4.67 (dd, J = 13.6 Hz, 3.7 Hz, 1H, H-6), 4.41 (dd, J = 13.7 Hz, 9.3
Hz, 1H, H-6), 4.31–4.17 (m, 1H, H-5), 2.33 (s, 3H, CH3) ppm. 13C NMR (75 MHz, DMSO) δ: 170.3 (C-1),
152.1 (C-3), 146.1 (C-8), 137.0 (Ph-q), 129.4 (Ph), 128.1 (Ph-q), 125.0 (Ph), 122.1 (C-7), 118.3 (C-2), 75.6
(C-4), 67.1 (C-5), 52.8 (C-6), 20.7 (CH3) ppm. HRMS (ESI Q-TOF): calculated for C15H15N3O5 [M + H]+
= 318.1090; found = 318.1090.
Preparation of 6-deoxy-6-[4-methoxyphenyl-1,2,3-triazol-1-yl]-L-ascorbic acid (4g): Compound 4g (81.8 mg;
54%; 185–187 ◦C) was synthesized according to the general procedure using compound 3g (234 mg;
0.456 mmol); 1 M BCl3 (2.74 mL) and CH2Cl2 (20 mL). 1H NMR (300 MHz, DMSO) δ: 11.18 (bs, 1H,
OH), 8.45 (s, 2H, H-7, OH), 7.77 (d, J = 8.8 Hz, 2H, Ph), 7.01 (d, J = 8.8 Hz, 2H, Ph), 5.53 (bs, 1H, OH),
4.76 (d, J = 1.5 Hz, 1H, H-4), 4.66 (dd, J = 13.7 Hz, 3.9 Hz, 1H, H-6), 4.40 (dd, J = 13.7 Hz, 9.3 Hz, 1H,
H-6), 4.28–4.19 (m, 1H, H-5), 3.79 (s, 3H, OCH3) ppm. 13C NMR (75 MHz, DMSO) δ: 170.3 (C-1), 158.9
(Ph-q), 152.0 (C-3), 145.9 (C-8), 126.4 (Ph), 123.4 (Ph-q), 121.5 (C-7), 118.3 (C-2), 114.3 (Ph), 75.5 (C-4),
67.1 (C-5), 55.1 (OCH3), 52.7 (C-6) ppm. HRMS (ESI Q-TOF): calculated for C34H45NO16 [M + H]+ =
334.1039; found = 334.1025.
Preparation of 6-deoxy-6-[2-hydroxyphenyl-1,2,3-triazol-1-yl]-L-ascorbic acid (4i): Compound 4i (56.5 mg;
63%; m.p. = 129–131 ◦C) was synthesized according to the general procedure using compound 3h (145
mg; 0.282 mmol); 1 M BCl3 (1.69 mL) and CH2Cl2 (20 mL). 1H NMR (300 MHz, DMSO) δ: 11.13 (bs,
1H, OH), 10.20 (s, 1H, OH), 8.56–8.28 (m, 2H, H-7, OH), 8.01 (dd, J = 7.7 Hz, 1.5 Hz, 1H, Ph), 7.29–7.10
(m, 1H, Ph), 7.01–6.86 (m, 2H, Ph), 5.53 (bs, 1H, OH), 4.77 (d, J = 1.4 Hz, 1H, H-4), 4.70 (dd, J = 13.7 Hz,
3.7 Hz, 1H, H-6), 4.46 (dd, J = 13.7 Hz, 9.4 Hz, 1H, H-6), 4.25 (bs, 1H, H-5) ppm. 13C NMR (151 MHz,
DMSO) δ: 170.4 (C-1), 153.8; 152.1 (C-3, Ph-q), 142.7 (C-8), 128.6 (Ph), 126.4 (Ph), 124.4 (C-7), 119.3
(Ph), 118.3 (C-2), 117.1 (Ph-q), 116.0 (Ph), 75.7 (C-4), 67.3 (C-5), 52.7 (C-6) ppm. HRMS (ESI Q-TOF):
calculated for C14H13N3O6 [M + H]+ = 320.0883; found = 320.0869.
Preparation of 6-deoxy-6-[4-(4-pentylphenyl)-1,2,3-triazol-1-yl]-L-ascorbic acid (4k): Compound 4k (62 mg;
57%; m.p. = 237–239 ◦C) was synthesized according to the general procedure using compound 3k
(162.0 mg; 0.293 mmol); 1 M BCl3 (1.8 mL) and CH2Cl2 (20 mL). 1H NMR (600 MHz, DMSO) δ: 11.14
(bs, 1H, OH), 8.49 (s, 1H, H-7), 8.43 (bs, 1H, OH), 7.74 (d, J = 8.2 Hz, 2H, Ph), 7.26 (d, J = 8.1 Hz, 2H,
Ph), 5.53 (bs, 1H, OH), 4.76 (d, J = 1.6 Hz, 1H, H-4), 4.67 (dd, J = 13.8 Hz, 4.0 Hz, 1H, H-6), 4.41 (dd,
J = 13.8 Hz, 9.3 Hz, 1H, H-6), 4.34–4.04 (m, 1H, H-5), 2.59 (t, J = 7.6 Hz, 2H, H-1′), 1.68–1.47 (m, 2H,
CH2′), 1.44–1.18 (m, 4H, CH2’), 0.87 (t, J = 7.0 Hz, 3H, CH3) ppm. 13C NMR (151 MHz, DMSO) δ:
170.2 (C-1), 152.0 (C-3), 146.1 (C-8), 142.0 (Ph-q), 128.7 (Ph), 128.3 (Ph-q), 125.0 (Ph), 122.1 (C-7), 118.3
(C-2), 75.5 (C-4), 67.1 (C-5), 52.7 (C-6), 34.8 (C-1′), 30.8 (CH2’), 30.5 (CH2’), 21.9 (CH2’), 13.9 (CH3) ppm.
HRMS (ESI Q-TOF): calculated for C19H23N3O5 [M + H]+ = 374.1716; found = 374.1700.
Preparation of 6-[4-cyclopropyl-1,2,3-triazol-1-yl]-6-deoxy-L-ascorbic acid (4l): Compound 4l (80.4 mg; 78%;
m.p. = 119–121 ◦C) was synthesized according to the general procedure using compound 3l (172.2 mg;
0.385 mmol); 1 M BCl3 (2.3 mL) and CH2Cl2 (20 mL). 1H NMR (600 MHz, DMSO) δ: 11.13 (bs, 1H, OH),
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8.43 (bs, 1H, OH), 7.80 (s, 1H, H-7), 5.44 (bs, 1H, OH), 4.68 (d, J = 1.2 Hz, 1H, H-4), 4.54 (dd, J = 13.8 Hz,
4.0 Hz, 1H, H-6), 4.29 (dd, J = 13.7 Hz, 9.2 Hz, 1H, H-6), 4.17–4.12 (m, 1 H, H-5), 2.11–1.44 (m, 1H, H-1′),
0.96–0.82 (m, 2H, CH2’), 0.78–0.59 (m, 2H, CH2’) ppm. 13C NMR (75 MHz, DMSO) δ: 170.3 (C-1), 152.1
(C-3), 148.5 (C-8), 121.8 (C-7), 118.3 (C-2), 75.5 (C-4), 67.1 (C-5), 52.5 (C-6), 7.6 (CH2’), 7.5 (CH2’), 6.5
(C-1′) ppm. HRMS (ESI Q-TOF): calculated for C11H13N3O5 [M + H]+ = 268.0933; found = 268.0938.
Preparation of 6-(4-butyl-1,2,3-triazol-1-yl)-6-deoxy-L-ascorbic acid (4m): Compound 4m (36.5 mg; 47%;
m.p. = 98–99 ◦C) was synthesized according to the general procedure using compound 3m (127.9 mg;
0.276 mmol); 1 M BCl3 (1.7 mL) and CH2Cl2 (20 mL). 1H NMR (300 MHz, DMSO) δ: 11.14 (bs, 1H,
OH), 8.45 (bs, 1H, OH), 7.82 (s, 1H, H-7), 5.44 (d, J = 7.0 Hz, 1H, OH), 4.68 (d, J = 1.5 Hz, 1H, H-4),
4.56 (dd, J = 13.7 Hz, 4.1 Hz, 1H, H-6), 4.32 (dd, J = 13.7 Hz, 9.0 Hz, 1H, H-6), 4.22–4.12 (m, 1H, H-5),
2.63–2.57 (m, 2H, H-1′), 1.65–1.49 (m, 2H, CH2’), 1.45–1.19 (m, 2H, CH2’), 0.89 (t, J = 7.3 Hz, 3H, CH3)
ppm. 13C NMR (75 MHz, DMSO) δ: 170.3 (C-1), 152.1 (C-3), 146.5 (C-8), 122.8 (C-7), 118.3 (C-2), 75.6
(C-4), 67.2 (C-5), 52.4 (C-6), 31.1 (C-1′), 24.6 (CH2’), 21.7 (CH2’), 13.7 (CH3) ppm. HRMS (ESI Q-TOF):
calculated for C12H17N3O5 [M + H]+ = 284.1246; found = 284.1250.
Preparation of 6-(4-decyl-1,2,3-triazol-1-yl)-6-deoxy-L-ascorbic acid (4n): Compound 4n (59.1 mg; 42%;
m.p. = 140–142 ◦C) was synthesized according to the general procedure using compound 3n (209.1 mg;
0.382 mmol); 1 M BCl3 (1.6 mL) and CH2Cl2 (20 mL). 1H NMR (300 MHz, DMSO) δ: 11.14 (bs, 1H,
OH), 8.43 (bs, 1H, OH), 7.81 (s, 1H, H-7), 5.44 (d, J = 5.9 Hz, OH), 4.68 (d, J = 1.5 Hz, 1H, H-4), 4.56 (dd,
J = 13.7 Hz, 4.0 Hz, 1H, H-6), 4.32 (dd, J = 13.6 Hz, 9.1 Hz, 1H, H-6), 4.22–4.11 (m, 1H, H-5), 2.59 (t,
J = 7.5 Hz, 2H, H-1′), 1.67–1.43 (m, 2H, H-2′), 1.36–1.17 (m, 14H, CH2’), 0.85 (t, J = 6.6 Hz, 3H, CH3)
ppm. 13C NMR (75 MHz, DMSO) δ: 170.3 (C-1), 152.0 (C-3), 146.6 (C-8), 122.8 (C-7), 118.3 (C-2), 75.6
(C-4), 67.2 (C-5), 52.4 (C-6), 31.3 (C-1′), 29.0 (CH2’), 28.8 (CH2’), 28.7 (CH2’), 28.6 (CH2’), 25.0 (CH2’),
22.1 (CH2’), 143.0 (CH3) ppm. HRMS (ESI Q-TOF): calculated for C18H29N3O5 [M + H]+ = 368.2185;
found = 368.2175.
Preparation of 6-[4-(tert-butyl)-1,2,3-triazol-1-yl]-6-deoxy-L-ascorbic acid (4o): Compound 4o (64.5 mg; 48%;
m.p. ≥ 250 ◦C) was synthesized according to the general procedure using compound 3o (220.0 mg;
0.475 mmol); 1 M BCl3 (2.9 mL) and CH2Cl2 (20 mL). 1H NMR (300 MHz, DMSO) δ: 11.17 (bs, 1H,
OH), 8.45 (bs, 1H, OH), 7.83 (s, 1H, H-7), 5.45 (bs, 1H, OH), 4.70 (d, J = 1.2 Hz, 1H, H-4), 4.56 (dd,
J = 13.6 Hz, 3.8 Hz, 1H, H-6), 4.32 (dd, J = 13.5 Hz, 9.1 Hz, 1H, H-6), 4.25–4.12 (m, 1H, H-5), 1.27 (s, 9H,
3 × CH3) ppm. 13C NMR (75 MHz, DMSO) δ: 170.3 (C-1), 155.9 (C-8), 152.1 (C-3), 120.8 (C-7), 118.3
(C-2), 75.6 (C-4), 67.2 (C-5), 52.4 (C-6), 30.3 (3 × CH3), 28.9 (C-1′) ppm. HRMS (ESI Q-TOF): calculated
for C12H17N3O5 [M + H]+ = 284.1246; found = 284.1247.
Preparation of 6-[4-(3-chloropropyl)-1,2,3-triazol-1-yl]-6-deoxy-L-ascorbic acid (4p): Compound 4p (104.0 mg;
83%; m.p. = 86–88 ◦C) was synthesized according to the general procedure using compound 3p (200.0
mg; 0.413 mmol); 1 M BCl3 (2.5 mL) and CH2Cl2 (20 mL). 1H NMR (300 MHz, DMSO) δ: 11.17 (s, 1H,
OH), 8.47 (s, 1H, OH), 7.88 (s, 1H, H-7), 5.47 (d, J = 7.2 Hz, 1H, OH), 4.71 (d, J = 1.4 Hz, 1H, H-4), 4.58
(dd, J = 13.7 Hz, 3.9 Hz, 1H, H-6), 4.33 (dd, J = 13.7 Hz, 9.2 Hz, 1H, H-6), 4.26–4.11 (m, 1H, H-5), 3.68 (t,
J = 6.5 Hz, 2H, H-3′), 2.75 (t, J = 7.4 Hz, 2H, H-1′), 2.08–2.01 (m, 2H, H-2′) ppm. 13C NMR (151 MHz,
DMSO) δ: 170.3 (C-1), 152.1 (C-3), 145.2 (C-8), 123.2 (C-7), 118.3 (C-2), 75.6 (C-4), 67.2 (C-5), 52.5 (C-6),
44.7 (C-3′), 31.8 (C.-1′), 22.3 (C-2′) ppm. HRMS (ESI Q-TOF): calculated for C11H14ClN3O5 [M + H]+ =
304.0700; found = 304.0697.
Preparation of 6-deoxy-6-(4-(2-hydroxyethyl)-1,2,3-triazol-1-yl)-L-ascorbic acid (4q): Compound 4q (59.5 mg;
70%; m.p. = 184–186 ◦C) was synthesized according to the general procedure using compound 3q
(140.3 mg; 0.311 mmol); 1 M BCl3 (1.9 mL) and CH2Cl2 (20 mL). 1H NMR (600 MHz, DMSO) δ: 11.17
(bs, 1H, OH), 8.46 (bs, 1H, OH), 7.85 (s, 1H, H-7), 5.46 (bs, 1H, OH), 4.73–4.66 (m, 2H, H-4, OH), 4.57
(dd, J = 13.8 Hz, 4.0 Hz, 1H, H-6), 4.33 (dd, J = 13.8 Hz, 9.2 Hz, 2H, H-6), 4.25–4.10 (m, 2H, H-5),
3.64–3.60 (m, 2H, H-2′), 2.76 (t, J = 7.0 Hz, 2H, H-1′) ppm. 13C NMR (151 MHz, DMSO) δ: 170.4 (C-1),
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152.1 (C-3), 144.1 (C-8), 123.5 (C-7), 118.3 (C-2), 75.6 (C-4), 67.2 (C-5), 60.4 (C-2′), 52.4 (C-6), 29.2 (C-1′)
ppm. HRMS (ESI Q-TOF): calculated For C10H13N3O6 [M + H]+ = 272.0883; found = 272.0895.
Preparation of 6-deoxy-6-[(4-(4-methylbenzenesulphonamide)methyl-1,2,3-triazol-1-yl]-L-ascorbic acid (4r):
Compound 4r (115.9 mg; 85%; m.p. = 125–127 ◦C) was synthesized according to the general procedure
using compound 3r (196.0 mg; 0.330 mmol); 1 M BCl3 (2.0 mL) and CH2Cl2 (20 mL). 1H NMR (600 MHz,
DMSO) δ: 11.15 (bs, 1H, OH), 8.44 (bs, 1H, OH), 8.03 (t, J = 6.0 Hz, 1H, NH), 7.83 (s, 1H, H-7), 7.68 (d,
J = 8.2 Hz, 2H, Ph), 7.38 (d, J = 8.0 Hz, 2H, Ph), 5.44 (d, J = 7.4 Hz, 1H, OH), 4.64 (d, J = 1.5 Hz, 1H,
H-4), 4.55 (dd, J = 13.8 Hz, 4.2 Hz, 1H, H-6), 4.32 (dd, J = 13.8 Hz, 9.1 Hz, 1H, H-6), 4.16–4.11 (m, 1H,
H-5), 4.01 (d, J = 6.0 Hz, 2H, CH2NH), 2.38 (s, 3H, CH3) ppm. 13C NMR (75 MHz, DMSO) δ: 170.3
(C-1), 152.0 (C-8), 143.13 (C-3), 142.65 (Ph-q), 137.5 (Ph-q), 129.6 (Ph), 126.6 (Ph), 124.2 (C-7), 118.3 (C-2),
75.5 (C-4), 67.2 (C-5), 52.4 (C-6), 38.1 (CH2NH), 21.0 (CH3) ppm. HRMS (ESI Q-TOF): calculated for
C16H18N4O7S [M + H]+ = 411.0974; found = 411.0961.
Preparation of 6-[(4-(4-chlorobenzenesulphonamide)methyl-1,2,3-triazol-1-yl]-6-deoxy-L-ascorbic acid (4s):
Compound 4s (87.0 mg; 80%; m.p. = 132–134 ◦C) was synthesized according to the general procedure
using compound 3s (154.0 mg; 0.252 mmol); 1 M BCl3 (1.5 mL) and CH2Cl2 (20 mL). 1H NMR (300 MHz,
DMSO) δ: 11.17 (bs, 1H, OH), 8.45 (bs, 1H, OH), 8.26 (t, J = 5.9 Hz, 1H, NH), 7.88 (s, 1H, H-7), 7.81–7.71
(m, 2H, Ph), 7.67–7.61 (m, 2H, Ph), 5.46 (d, J = 7.4 Hz, 1H, OH), 4.67 (d, J = 1.5 Hz, 1H, H-4), 4.56
(dd, J = 13.7 Hz, 4.0 Hz, 1H, H-6), 4.32 (dd, J = 13.6 Hz, 9.1 Hz, 1H, H-6), 4.18–4.09 (m, 1H, H-5), 4.06
(d, J = 6.0 Hz, 2H, CH2NH) ppm. 13C NMR (75 MHz, DMSO) δ: 170.1 (C-1), 152.0 (C-3), 142.9 (C-8),
139.3 (Ph-q), 137.2 (Ph-q), 129.2 (Ph), 128.5 (Ph), 124.3 (C-7), 118.4 (C-2), 75.5 (C-4), 67.2 (C-5), 52.5
(C-6), 38.0 (CH2NH) ppm. HRMS (ESI Q-TOF): calculated for C15H5ClN4O7S [M + H]+ = 431.0428;
found = 431.0412.
Preparation of 6-[(4-(2-chloro-4-fluorobenzenesulphonamide)methyl-1,2,3-triazol-1-yl]-6-deoxy-L-ascorbic acid
(4t): Compound 4t (88.7 mg; 59%; m.p. = 198–200 ◦C) was synthesized according to the general
procedure using compound 3t (210.0 mg; 0.334 mmol); 1 M BCl3 (2.0 mL) and CH2Cl2 (20 mL). 1H NMR
(300 MHz, DMSO) δ: 11.18 (bs, 1H), 8.45 (t, J = 5.9 Hz, 1H, NH), 7.96 (dd, J = 8.9, 6.0 Hz, 1H, Ph), 7.83
(s, 1H, H-7), 7.62 (dd, J = 8.7, 2.5 Hz, 1H, Ph), 7.36 (td, J = 8.6, 2.6 Hz, 1H, Ph), 4.65 (d, J = 1.3 Hz, 1H,
H-4), 4.54 (dd, J = 13.8 Hz, 4.0 Hz, 1H, H-6), 4.30 (dd, J = 13.7 Hz, 9.1 Hz, 1H, H-6), 4.17 (d, J = 5.9 Hz,
2H, CH2NH), 4.14–4.06 (m, 1H, H-5) ppm. 13C NMR (75 MHz, DMSO) δ: 170.2 (C-1), 165.3; 161.9
(d, 1JCF = 254.3 Hz, Ph-4), 151.9 (C-3), 142.9 (C-8), 134.8; 137.7 (d, 4JCF = 3.6 Hz, Ph-1), 132.8; 132.6 (d,
3JCF = 10.1 Hz, Ph-6), 132.6; 132.4 (d, 3JCF = 10.1 Hz, Ph-2), 124.2 (C-7), 119.2; 118.9 (d, 2JCF = 25.9 Hz,
Ph), 118.3 (C-2), 114.8; 114.5 (d, 2JCF = 21.8 Hz, Ph), 75.5 (C-4), 67.2 (C-5), 52.4 (C-6), 37.8 (CH2NH)
ppm. HRMS (ESI Q-TOF): calculated for C15H14ClFN4O7S [M + H]+ = 449.0334; found = 449.0326.
Preparation of 6-[4-((tert-butyl 1-carboxylate)-4-(methylthiocarbothionyl)piperazine))-1,2,3-triazol-1-yl]-6-deoxy-
L-ascorbic acid (4v): Compound 4v (31.2 mg; 35%; m.p. ≥ 250 ◦C) was synthesized according to the
general procedure using compound 3u (147.7 mg; 0.221 mmol); 1 M BCl3 (1.3 mL) and CH2Cl2 (15 mL).
1H NMR (600 MHz, DMSO) δ: 9.74 (bs, 1H, NH), 8.52 (bs, 1H, OH), 8.08 (s, 1H, H-7), 5.46 (bs, 1H, OH),
4.71 (d, J = 1.5 Hz, 1H, H-4), 4.67–4.54 (m, 3H, H-6, CH2S), 4.39–4.11 (m, 4H, H-6, H-5, 2 × CH2), 3.2–3.1
(m, 4H, 2 × CH2) ppm. 13C NMR (151 MHz, DMSO) δ: 195.8 (CS), 170.1 (C-1), 151.7 (C-3), 141.2 (C-8),
124.8 (C-7), 118.3 (C-2), 75.6 (C-4), 67.2 (C-5), 52.7 (C-6), 42.3 (CH2’), 31.9 (CH2S) ppm. HRMS (ESI
Q-TOF): calculated for C14H19N5O5S2 [M + H]+ = 402.0906; found = 402.0891.
Preparation of 4,5-didehydro-5,6-dideoxy-(4-(3,5-di-(trifluoromethyl)phenyl)-1,2,3-triazol-1-yl)-L-ascorbic acid
(7c): Compound 7c (72.1 mg; 52%; m.p. ≥ 200 ◦C) was synthesized according to the general procedure
using compound 6c (200 mg; 0.33 mmol); 1 M BCl3 (1.98 mL) and CH2Cl2 (20 mL). 1H-NMR (300 MHz,
DMSO) δ: 11.21 (s, 1H, OH), 9.95 (s, 1H, OH), 9.01 (s, 1H, H-7), 8.54 (s, 2H, Ph-2, Ph-6), 8.07 (s, 1H,
Ph-4), 5.61 (t, J = 7.6 Hz, 1H, H-5), 5.30 (d, J = 7.7 Hz, 2H, H-6) ppm. 13C-NMR (151 MHz, DMSO) δ:
164.6 (C-1), 145.8 (C-3), 143.8 (C-4), 142.9 (C-8), 133.2 (Ph-1), 131.3; 131.1; 130.9; 130.7 (q, 2JCF = 33.0 Hz,
Ph-3, Ph-5), 125.9; 124.1; 122.3 (m, 1JCF = 272.8 Hz, CF3), 125.3 (Ph-2, Ph-6), 123.3 (C-7), 122.1 (C-2),
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121.1 (Ph-4), 98.2 (C-5), 44.5 (C-6) ppm. HRMS (ESI Q-TOF): calculated for C16H9F6N3O4 [M + H]+ =
422.0576; found = 422.0580.
Preparation of 4,5-didehydro-5,6-dideoxy-(4-(3,5-difluoromethyl)phenyl)-1,2,3-triazol-1-yl)-L-ascorbic acid (7d):
Compound 7d (61.1 mg; 48%; m.p. ≥ 200 ◦C) was synthesized according to the general procedure
using compound 6d (200 mg; 0,39 mmol); 1 M BCl3 (2.27 mL) and CH2Cl2 (20 mL): Compound 7d was
isolated as white powder. 1H-NMR (600 MHz, DMSO) δ: 11.31 (s, 1H, OH), 9.83 (s, 1H, OH), 8.75 (s,
1H, H-7), 7.59 (d, J = 6.6 Hz, 2H, Ph-2, Ph-6), 7.31–7.03 (m, 1H, Ph-4), 5.58 (t, J = 7.7 Hz, 1H, H-5), 5.26
(d, J = 7.7 Hz, 2H, H-6) ppm. 13C-NMR (151 MHz, DMSO) δ: 164.6 (C-1), 163.7; 163.6; 162.1; 162.0 (dd,
1JCF = 245.6 Hz, 3JCF = 13.7 Hz, Ph-3, Ph-5), 145.7 (C-3), 144.6 (C-8), 142.9 (C-4), 134.2; 134.2; 134.1 (t,
J = 10.5 Hz, Ph-1), 122.7 (C-7), 122.1 (C-2), 108.2; 108.1; 108.0; 108.0 (dd, 2JCF = 21.1 Hz, 4JCF = 5.5 Hz,
Ph-2, Ph-6), 103.2; 103.1; 102.9 (t, 2J = 26.0 Hz, Ph-4), 98.4 (C-5), 44.5 (C-6) ppm. HRMS (ESI Q-TOF):
calculated for C14H9F2N3O4 [M + H]+ = 322.0639; found = 322.0642.
Preparation of 6-[4-(4-bromophenyl)-1,2,3-triazole-1-yl]-4,5-didehydro-5,6-dideoxy-L-ascorbic acid (7e):
Compound 7e (24 mg; 21%; m.p. = 219–222 ◦C) was synthesized according to the general procedure
using compound 6e (177 mg; 0.324 mmol); 1 M BCl3 (1.94 mL) and CH2Cl2 (20 mL). 1H NMR (300 MHz,
DMSO) δ: 10.48 (s, OH), 8.67 (s, 1H, H-7), 7.82 (d, J = 8.5 Hz, 2H, Ph), 7.64 (d, J = 8.6 Hz, 2H, Ph), 5.58
(t, J = 7.5 Hz, 1H, H-5), 5.25 (d, J = 7.5 Hz, 2H, H-6). 13C NMR (75 MHz, DMSO-d6) δ: 164.7 (C-1),
145.5 (C-3), 143.0 (C-8, C-4), 131.8 (Ph), 129.9 (Ph-q), 127.1 (Ph), 122.0 (C-7), 121.8 (C-2), 120.8 (Ph-q),
98.7 (C-5), 44.4 (C-6) ppm. HRMS (ESI Q-TOF): calculated for C14H10BrN3O4 [M + H]+ = 363.9933;
found = 363.9915.
Preparation of 6-[4-tolyl-1,2,3-triazole-1-yl]-4,5-didehydro-5,6-dideoxy-L-ascorbic acid (7f): Compound 7f
(20 mg; 15%; m.p. = 188–192 ◦C) was synthesized according to the general procedure using compound
6f (203 mg; 0.407 mmol); 1 M BCl3 (2.45 mL) and CH2Cl2 (20 mL). 1H NMR (600 MHz, DMSO) δ: 11.40
(s, 1H, OH), 9.78 (s, 1H, OH), 8.56 (s, 1H, H-7), 7.74 (d, J = 8.0 Hz, 2H, Ph), 7.25 (d, J = 7.9 Hz, 2H, Ph),
5.59 (t, J = 7.6 Hz, 1H, H-5), 5.24 (d, J = 7.6 Hz, 2H, H-6), 2.33 (s, 3H, CH3) ppm. 13C NMR (151 MHz,
DMSO) δ: 164.7 (C-1), 146.5 (C-3), 145.3 (C-4), 143.0 (C-8), 137.2 (Ph-q), 129.4 (Ph), 127.9 (Ph-q), 125.0
(Ph), 121.9 (C-7), 120.9 (C-2), 98.8 (C-5), 44.3 (C-6), 20.7 (CH3) ppm. HRMS (ESI Q-TOF): calculated for
C15H13N3O4 [M + H]+ = 300.0984; found 300.0974.
Preparation of 4,5-didehydro-5,6-dideoxy-6-[4-(4-methoxyphenyl)-1,2,3-triazole-1-yl]-L-ascorbic acid (7g):
Compound 7g (58.1 mg; 28%; m.p. = 198–199 ◦C) was synthesized according to the general procedure
using compound 6g (328 mg; 0.662 mmol); 1 M BCl3 (3.96 mL) and CH2Cl2 (25 mL). 1H NMR (600 MHz,
DMSO) δ: 11.05 (bs, 1H, OH), 9.95 (bs, 1H, OH), 8.49 (s, 1H, H-7), 7.78 (d, J = 8.7 Hz, 2H, Ph), 7.01
(d, J = 8.7 Hz, 2H, Ph), 5.58 (t, J = 7.6 Hz, 1H, H-5), 5.23 (d, J = 7.6 Hz, 2H, H-6) ppm. 13C NMR (151
MHz, DMSO) δ: 164.7 (C-1), 159.0 (Ph-q), 146.5 (C-3), 145.3 (C-8), 126.5 (Ph), 123.3 (Ph-q), 121.9 (C-2),
120.4 (C-7), 114.3 (Ph), 99.0 (C-5), 55.1 (OCH3), 44.3 (C-6) ppm. HRMS (ESI Q-TOF): calculated for
C15H13N3O5 [M + H]+ = 316.0933; found = 316.0930.
Preparation of 4,5-didehydro-5,6-dideoxy-6-[4-(2-hydroxyphenyl)-1,2,3-triazole-1-yl]-L-ascorbic acid (7i):
Compound 7i (64.2 mg; 56%; m.p. = 167–169 ◦C) was synthesized according to the general procedure
using compound 6h (188 mg; 0.379 mmol); 1 M BCl3 (2.28 mL) and CH2Cl2 (20 mL). 1H NMR (300 MHz,
DMSO) δ: 11.13 (bs, 1H, OH), 10.15 (s, 1H, OH), 9.74 (bs, 1H, OH), 8.41 (s, 1H, H-7), 7.97 (dd, J = 7.7 Hz,
1.7 Hz, 1H, Ph), 7.43–7.05 (m, 1H, Ph), 6.99–6.78 (m, 2H, Ph), 5.58 (t, J = 7.5 Hz, 1H, H-5), 5.25 (d,
J = 7.5 Hz, 2H, H-6) ppm. 13C NMR (75 MHz, DMSO) δ: 164.6 (C-1), 153.9 (Ph-q), 145.1 (C-3), 143.1
(C-8), 143.0 (C-4), 128.7 (Ph), 126.5 (Ph), 123.1 (C-7), 121.9 (C-2), 119.2 (Ph), 116.9 (Ph-q), 115.9 (Ph),
99.3 (C-5), 44.2 (C-6) ppm. HRMS (ESI Q-TOF): calculated for C14H11N3O5 [M + H]+ = 302.0777;
found = 302.0782.
Preparation of 4,5-didehydro-5,6-dideoxy-6-[4-(3-hydroxyphenyl)-1,2,3-triazole-1-yl]-L-ascorbic acid (7j):
Compound 7j (45.3 mg; 41%; m.p. = 155–157 ◦C) was synthesized according to the general procedure
using compound 6j (175 mg; 0.363 mmol); 1 M BCl3 (2.18 mL) and CH2Cl2 (20 mL). 1H NMR (600 MHz,
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DMSO) δ: 11.33 (s, 1H, OH), 9.90 (s, 1H, OH), 9.55 (s, 1H, OH), 8.55 (s, 1H, H-7), 7.54–7.02 (m, 3H, Ph),
6.72 (d, J = 7.0 Hz, 1H, Ph), 5.59 (t, J = 7.6 Hz, 1H, H-5), 5.23 (d, J = 7.6 Hz, 2H, H-6) ppm. 13C NMR
(151 MHz, DMSO) δ: 164.7 (C-1), 157.8 (Ph-q), 146.7 (C-3), 145.3 (C-4), 143.0 (C-8), 131.9 (Ph-q), 130.0
(Ph), 122.0 (C-7), 121.4 (C-2), 116.1 (Ph), 114.9 (Ph), 111.9 (Ph), 99.0 (C-5), 44.4 (C-6) ppm. HRMS (ESI
Q-TOF): calculated for C14H11N3O5 [M + H]+ = 302.0777; found = 302.0765.
Preparation of 4,5-didehydro-5,6-dideoxy-6-[4-(4-pentylphenyl)-1,2,3-triazole-1-yl]-L-ascorbic acid (7k):
Compound 7k (31 mg; 24%; m.p. = 230–232 ◦C) was synthesized according to the general procedure
using compound 6k (195 mg; 0.364 mmol); 1 M BCl3 (2.18 mL) and CH2Cl2 (20 mL). 1H NMR (300 MHz,
DMSO) δ: 11.10 (bs, 1 H, OH), 9.98 (bs, 1H, OH), 8.55 (s, 1H, H-7), 7.75 (d, J = 8.1 Hz, 2H, Ph), 7.26 (d,
J = 8.1 Hz, 2H, Ph), 5.59 (t, J = 7.6 Hz, 1H, H-5), 5.24 (d, J = 7.6 Hz, 1H, H-6), 2.59 (t, J = 7.6 Hz, 2H, H-1′),
1.65–1.51 (m, 2H, CH2), 1.38–1.17 (m, 4H, CH2), 0.86 (t, J = 6.8 Hz, 3H, CH3) ppm. 13C NMR (75 MHz,
DMSO) δ: 164.7 (C-1), 146.6 (C-3), 145.3 (C-4), 143.0 (C-8), 142.1 (Ph-q), 128.8 (Ph), 128.1 (Ph-q), 125.1
(Ph), 122.0 (C-2), 121.0 (C-7), 99.0 (C-5), 44.3 (C-6), 34.8 (C-1′), 30.9 (C-2′), 30.5 (CH2), 21.9 (CH2), 13.9
(CH3) ppm. HRMS (ESI Q-TOF): calculated for C19H21N3O4 [M + H]+ = 356.1610; found = 356.1598.
Preparation of 6-[4-cyclopropyl-1,2,3-triazole-1-yl]-4,5-didehydro-5,6-dideoxy-L-ascorbic acid (7l): Compound
7l (52.5 mg; 53%; m.p. = 176–178 ◦C) was synthesized according to the general procedure using
compound 6l (170 mg; 0.396 mmol); 1 M BCl3 (2.38 mL) and CH2Cl2 (20 mL). 1H NMR (300 MHz,
DMSO) δ: 11.10 (bs, 1H, OH), 9.88 (bs, 1H, OH), 7.83 (s, 1H, H-7), 5.50 (t, J = 7.5 Hz, 1H, H-5), 5.11
(d, J = 7.6 Hz, 2H, H-6), 1.98–1.86 (m, 1H, CH), 0.95–0.84 (m, 2H, CH2), 0.73–0.65 (m, 2H, CH2) ppm.
13C NMR (75 MHz, DMSO) δ: 164.6 (C-1), 149.2 (C-8), 145.0 (C-3), 143.0 (C-4), 121.9 (C-2), 120.6 (C-7),
99.2 (c-5), 44.0 (C-6), 7.5 (CH2), 6.4 (CH) ppm. HRMS (ESI Q-TOF): calculated for C11H11N3O4 [M + H]
+ = 250.0828; found = 250.0826.
Preparation of 6-[4-butyl-1,2,3-triazole-1-yl]-4,5-didehydro-5,6-dideoxy-L-ascorbic acid (7m): Compound
7m (66.8 mg; 47%; m.p. = 180–183 ◦C) was synthesized according to the general procedure using
compound 6m (237 mg; 0.532 mmol); 1 M BCl3 (3.19 mL) and CH2Cl2 (20 mL). 1H NMR (600 MHz,
DMSO) δ: 11.32 (s, 1H, OH), 9.76 (s, 1H, OH), 7.88 (s, 1H, H-7), 5.52 (t, J = 7.6 Hz, 1H, H-5), 5.14 (d,
J = 7.6 Hz, 2H, H-6), 2.60 (t, J = 7.6 Hz, 2H, H-1′), 1.68–1.42 (m, 2H, CH2), 1.41–1.26 (m, 2H, CH2), 0.89
(t, J = 7.4 Hz, 3H, CH3) ppm. 13C NMR (151 MHz, DMSO) δ: 164.7 (C-1), 147.2; 145.0; 143.1 (C-3, C-4,
C-8), 121.9 (C-2), 121.8 (C-7), 99.4 (C-5), 44.0 (C-6), 31.1 (C-1′), 24.7 (CH2), 21.7 (CH2), 13.7 (CH3) ppm.
Preparation of 6-(4-decyl-1,2,3-triazol-1-il)-4,5-didehydro-5,6-dideoxy-L-ascorbic acid (7n): Compound 7n
(55 mg; 42%; m.p. = 169–171 ◦C) was synthesized according to the general procedure using compound
6n (200 mg; 0.38 mmol); 1 M BCl3 (2.28 mL) and CH2Cl2 (20 mL). 1H-NMR (600 MHz, DMSO) δ:
11.28 (s, 1H, OH), 9.73 (s, 1H, OH), 7.86 (s, 1H, H-7), 5.52 (t, 1H, J = 7.5 Hz, H-5), 5.14 (s, 2H, H-6),
2.60–2.57 (m, 2H, H-1′), 1.58–1.56 (m, 2H, H-2′), 1.33–1.20 (m, 14H, CH2), 0.84 (t, J = 7.0 Hz, 3H, CH3)
ppm. 13C-NMR (151 MHz, DMSO) δ: 164.6 (C-1), 147.2 (C-3), 144.9 (C-4), 143.0 (C-8), 121.9 (C-2), 121.7
(C-7), 99.3 (C-5), 43.9 (C-6), 31.2 (C-1′), 28.9 (CH2’), 28.7 (CH2’), 28.6 (CH2’), 28.5 (CH2’), 24.9 (CH2’),
22.1 (CH2’), 13.9 (CH3) ppm. HRMS (ESI Q-TOF): calculated for C18H27N3O4 [M + H] + = 350.2080;
found = 350.2086.
Preparation of 6-[4-tert-butyl-1,2,3-triazole-1-yl]-4,5-didehydro-5,6-dideoxy-L-ascorbic acid (7o): Compound
7o (30 mg; 24%; m.p. = 182–184 ◦C) was synthesized according to the general procedure using
compound 6o (203 mg; 0.455 mmol); 1 M BCl3 (2.72 mL) and CH2Cl2 (20 mL). 1H NMR (300 MHz,
DMSO) δ: 11.31–9.54 (bs, 2H, OH × 2), 7.88 (s, 1H, H-7), 5.53 (t, J = 7.5 Hz, 1H, H-5), 5.14 (d, J = 7.5 Hz,
2H, H-6), 1.27 (s, 9H, CH3 × 3). 13C NMR (75 MHz, DMSO) δ: 164.6 (C-1), 144.9 (C-3), 143.0 (C-4), 121.9
(C-2), 119.7 (C-7), 99.3 (C-5), 43.9 (C-6), 30.2 (C-1′), 30.2 (CH3) ppm. HRMS (ESI Q-TOF): calculated for
C12H15N3O4 [M + H] + = 266.1141; found = 266.1129.
Preparation of 6-[4-chloropropyl-1,2,3-triazole-1-yl]-4,5-didehydro-5,6-dideoxy-L-ascorbic acid (7p): Compound
7p (53.2 mg; 38%; m.p. = 160–162 ◦C) was synthesized according to the general procedure using
compound 6p (230 mg; 0.494 mmol); 1 M BCl3 (2.96 mL); CH2Cl2 (20 mL). 1H NMR (300 MHz, DMSO)
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δ: 11.18–9.67 (bs, 2H, OH × 2), 7.93 (s, 1H, H-7), 5.53 (t, J = 7.5 Hz, 1H, H-5), 5.15 (d, J = 7.5 Hz, 2H,
H-6), 3.67 (t, J = 6.5 Hz, 2H, H-3′), 2.82–2.66 (m, 2H, H-1′), 2.10–1.98 (m, 2H, H-2′) ppm. 13C NMR
(75 MHz, DMSO) δ: 164.6 (C-1), 145.7; 145.0; 143.0 (C-3, C-4, C-8), 122.1 (C-7), 121.9 (C-2), 99.2 (C-5),
44.6 (C-1′), 44.0 (C-6), 31.7 (C-1′), 22.3 (C-3′) ppm. HRMS (ESI Q-TOF): calculated for C11H12ClN3O4
[M + H] + = 286.0595; found = 286.0599.
Preparation of 6-[4-(2-hydroxyethyl)-1,2,3-triazole-1-yl]-4,5-didehydro-5,6-dideoxy-L-ascorbic cid (7q): Compound
7q (81.2 mg; 70%; m.p. = 172–173 ◦C) was synthesized according to the general procedure using
compound 6q (200 mg; 0.461 mmol); 1 M BCl3 (2.77 mL); CH2Cl2 (20 mL). 1H NMR (300 MHz, DMSO)
δ: 11.21 (bs, 1H, OH), 9.87 (bs, 1H, OH), 7.87 (s, 1H, H-7), 5.52 (t, J = 7.6 Hz, 1H, H-5), 5.15 (d, J = 7.6 Hz,
2H, H-6), 4.65 (bs, 1H, OH), 3.62 (t, J = 6.9 Hz, 2H, H-2′), 2.76 (t, J = 6.9 Hz, H-1′) ppm. 13C NMR (75
MHz, DMSO) δ: 164.6 (C-1), 145.0 (C-3), 144.7 (C-8), 143.0 (C-4), 122.3 (C-7), 121.9 (C-2), 99.3 (C-5),
60.3 (C-2′), 43.9 (C-6), 29.1 (C-1′) ppm. HRMS (ESI Q-TOF): calculated for C10H11N3O5 [M + H] + =
254.0777; found = 254.0770.
3.2. Biological Evaluation
3.2.1. DPPH Assay
Antioxidant capacity of selected compounds was assessed by 2,2-diphenyl-1-picrylhydrazyl assay
(DPPH, Sigma Aldrich, Darmstadt, Germany), in which the antioxidant activity of compounds is
measured by the reaction between a stable radical of 1,1-diphenyl-2-picylhydrazil (DPPH•) and a
selected compound according to the manufacturer recommendations. Briefly, compounds 4b–4e,
4f–4h, 4k, 4l, 4o, 4p–4s, 4t, 4v, 7c–7f, 7i–7n, 7q, 7p, and 7o were tested at 0.06, 0.12, 0.18, 0.23, 0.25,
and 0.28 mM. L-ascorbic acid was used as the reference compound. Absorbance was measured 5
and 10 min after incubation of the compounds with the DPPH reagent. The reduction of DPPH with
selected compounds was monitored by measuring the absorbance at a wavelength of 517 nm on the
monochromator (Infinite M200 PRO, TECAN, Männedorf, Switzerland).
3.2.2. In Silico Approaches—DFT Calculations and PCA Analysis
The gas-phase (g) reaction parameters for radical scavenging models: bond dissociation enthalpy
(BDE), basicity, and electron transfer enthalpy (ETE), and their aqueous free energy (FE) counterparts
BDFE, pKa, and ETFE, respectively, were calculated by using thermochemical cycles [42] in the density
functional theory (DFT) model (U)M052X/6-311++G** implemented in Gaussian 09 [57,58]. The
gas-phase equilibrium geometries were optimized for species in neutral and anion closed-shell singlet
and neutral monoradical and radical anion open-shell doublet ground electronic states. The minima
were confirmed by absence of imaginary vibrational frequencies. Calculations were done for the
compounds with a free C5OH group in the 4R,5S-configuration as a starting L-ASA (series 4). The
compounds with a C4=C5 double bond were determined in Z-configuration (series 7) (Scheme 1) [59].
The free energies of hydratation ∆G*hyd were determined at the gas phase geometries by using the
SMD method [60]. The gas-phase thermodynamic reaction parameters were calculated in terms of the
sums of electronic and thermal enthalpies or free energies estimated at temperature of 298.15 K and
pressure of 1 atm. For the electron and the proton, values reported in the reference [61] were used.
Regarding free energies of hydratation ∆G◦hyd(H•), ∆G◦hyd (H+), and ∆G◦hyd (e−), the experimental
values of 27.8 kJ/mol [62], −1104.62 kJ/mol [63] and −148.5 kJ/mol [64] were used, respectively.
The PCA analyses were done by R package princomp [65]. The values of partition n-octanol/water
coefficients—clogP were calculated by DataWarrior by using SMILES as inputs [44].
3.2.3. Cell Culturing
Human tumor cell lines HeLa (cervical carcinoma), SW620 (colorectal adenocarcinoma, metastatic),
A549 (lung adenocarcinoma), MCF−7 (breast adenocarcinoma), CFPAC-1 (pancreatic adenocarcinoma,
metastatic), HCT-116 (colorectal carcinoma), and HepG2 (hepatocellular carcinoma), and normal cell
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lines HFF-1 (foreskin fibroblasts) and WI-38 (immortalized human lung fibroblast), were from the
US American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in a liquid
nutrient medium (Dulbecco’s Modified Eagle Medium, LONZA, Basel, Switzerland) supplemented
with 10% fetal bovine serum (FBS, Gibco, Grand Island, NY, USA), 2 mM L-glutamine (GIBCO, Grand
Island, NY, USA), 100 µg/mL penicillin, and 100 µg/mL streptomycin (LONZA, Basel, Switzerland), in
an incubator (NÜVE, Ankara, Turkey), at a humid atmosphere with 5% CO2 at 37 ◦C. Trypsin/EDTA
Solution (Lonza, Basel, Switzerland), was used for cell passaging and cell detachment.
3.2.4. Proliferation Assay- MTT Assay
Adherent cells were seeded on 96 well microtiter plates (Falcon, New York, NY, USA) at a seeding
density of 5000 cells per well, added in 150 µL of cell suspension in a nutrient medium. 24 h after
seeding, cells were treated with compound 4b–4g, 4i, 4k–4t, 4v, 7c–7g, and 7i–7q dilutions in the range
of 0.01 µM to 100 µM. L-ascoric acid (Sigma Aldrich, Darmstadt, Germany) and Carboxyamidotriazole
(Sigma Aldrich, Darmstadt, Germany) were used as control compounds. Incubation of the cells
with the compounds were performed for 72 h in a 5% CO2, in humid atmosphere at 37 ◦C. After
incubation, nutrient medium was removed and 40µL of the MTT reagent (3-(4-dimethylthiazol-2-yl)-2,5-
diphenyltetrazole bromide (Invitrogen, Carlsbad, CA, USA) was added to each well. 3 h after incubation,
160 µL of DMSO (VWR CHEMICALS, Radnor, PA, USA) were added to each well to dissolve the crystals
of purple formazane. The absorbance was measured at 570 nm (TECAN SUNRISE Microtiter plate
reader (Männedorf, Switzerland). The experimentally measured optical densities (OD) were converted
to the PG (percentage of growth), using the formulas according to the protocol assumed by NIH
(National Institute of Health). The IC50 values (concentration causing 50% cell growth inhibition) for
each compound were calculated by regression analysis of the survival count curve of the concentrations
of the tested compounds. The results were processed in Excel 2010 (Microsoft, Redmond, WA, USA).
3.2.5. Apoptosis Detection—Annexin V Assay
A total of 2 × 104 MCF-7 cells were seeded into 8-well Nunc Lab-Tek II Chamber Slide system
(Thermo Fischer Scientific, Waltham, MA, USA), and treated with compound 4e at 1 × IC50 and 2 ×
IC50 for 24 and 48 h. The assay (Annexin-V-FLUOS Staining kit, Roche Applied Science, Penzberg,
Germany) was preformed according to the manufacturer protocol. Slides were analyzed by fluorescence
microscopy (Zeiss Axio Observer Z1 Inverted Phase Contrast Fluorescent Microscope, Jena, Germany)).
3.2.6. Western Blot Analysis
MCF-7 cells were seeded in Petri dishes, at 1 × 106 cells, and treated with compound 4e at IC50
6.72 µM for 24 and 48 h. Protein lysates were prepared using RIPA buffer containing cocktail of protease
and phosphatase inhibitors (Roche, Basel, Switzerland). Amounts of 50 µg of proteins were resolved on
12% SDS polyacrylamide gels using the Mini-protean cell (Bio-Rad, Hercules, CA, USA). The membranes
were incubated with primary antibodies raised against hydroxy-HIF-1α (Pro564) (HIF-1α, 1:1000, rabbit
mAb, Cell Signaling Technology, NL) and NOS2 (1:500, mouse mAb, SantaCruzBiotechnology, Dallas,
TX, USA) at 4 ◦C overnight. A secondary antibody linked to anti-mouse (1:1000, Dako, Santa Clara, CA,
USA) was used. The signal was visualized by the Western Lightening Chemiluminescence Reagent
Plus Kit (Perkin Elmer, Massachusetts, MA, USA) on the ImageQuant LAS500 (GE Healthcare, Chicago,
IL, USA), and as a loading control, α-tubulin (1:1000, mouse mAb, Sigma, Sigma Aldrich, Darmstadt,
Germany) was used. The signal intensities of bands were normalized and compared in Quantity One
software (Bio-Rad, Hercules, CA, USA). Differences in protein relative expression status obtained by
western blot analysis were analyzed by two-tailed, paired t-tests (p < 0.05) in the Statistica software
package (v.12.0).
3.2.7. Seahorse XF Cell Myto Stress Test
The Seahorse XF Cell Mito Stress Test was used for measurements of mitochondrial respiration
by direct assessment of the oxygen consumption rate (OCR), of treated and untreated cells on the
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Seahorse XFe24 Analyzer, (Agilent, Santa Clara, CA, USA). Key parameters of the mitochondrial
function were measured by direct assessment of the OCR, by use of the Mito Stress Test (Agilent,
Agilent, Santa Clara, CA, USA). The Mito Stress Test uses modulators of respiration that target
components of the electron transport chain in the mitochondria. The compounds added to the
reaction were: oligomycin, mitochondrial oxidative phosphorylation uncoupler carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP), and the mix of rotenone and antymicin A. These were
directly injected to the cell growth medium containing cells treated with selected L-ASA derivatives to
determine the production of ATP, respiration at maximal level, and the non-mitochondrial respiration.
Measured parameters were used for calculation of the proton leakage, spare respiratory capacity, and
basal respiration. The assay was performed according to the manufacturer’s instructions (SeaHorse—
Mito Stress Test: Agilent, Santa Clara, CA, USA). Briefly, selected compound 4e was tested due to its
selective antiproliferative effect on MCF-7 cells. MCF-7 cells were treated for 24 h with compound 4e
at 3 different concentrations (at 12.72 µM, 25.44 µM and 50.88 µM) while the cells HFF-1 were treated
for 24 h with compound 4e at concentrations 50 µM, 100 µM, and 200 µM. L-ascorbic acid, was used as
control compound and tested at concentrations 50, 100, and 150 mM (same as those used for DPPH
assay) on MCF-7 and HFF-1 cells. The experiment was performed with biological duplicates.
4. Conclusions
With the aim to find compounds with superior antioxidant and antiproliferative activity compared
to L-ASA, two novel classes of L-ASA derivatives, 6-(1,2,3-triazolyl)-6-deoxy-L-ASA (series 4) with
the C4-C5(OH) group, and their analogues (series 7) with the C4=C5 double bond were synthesized.
The assessment of the antioxidant activity by DPPH• radical scavenging assay showed that the majority
of the 4,5-unsaturated L-ASA derivatives (series 7) showed better antioxidant activity compared to
their saturated analogues (series 4). Moreover, the introduction of an additional hydroxyl group at
1,2,3-triazole of the 4,5-unsaturated L-ASA derivatives (in 7i, 7j, and 7q) resulted in improvement
of the radical scavenging activity. An explanation of the observed differences in the DPPH• radical
scavenging activities of the L-ASA−triazole conjugates has been obtained using in silico analysis,
which showed that the triazole conjugates have an analogous radical scavenging mechanism to
L-ASA and that the most significant difference between saturated C4-C5(OH) and unsaturated C4=C5
derivatives is in acidity of C2-OH group. The active radical scavenging center in L-ASA derivatives
with a C4-C5(OH) fragment is the C3-OH group, while for majority unsaturated C4=C5 derivatives,
the radical scavenging center can be ascribed to C2-OH group. Furthermore, the antiproliferative
evaluation on seven malignant tumor cell lines proved that the linker connecting the lactone ring
and the 1,2,3-triazole moiety has an influence on the antitumor activity. Hence, 1,2,3-triazole L-ASA
derivatives with a hydroxyethylene C4-C5(OH) unit showed better growth-inhibition effects on tumor
cells compared to their 4,5-unsaturated C4=C5 analogues. Additionally, unsubstituted 1,2,3-triazolyl
derivative 4b was not cytotoxic toward any of the tested cell lines, which shows that C-4 substitution
at the 1,2,3-triazole moiety has an impact on growth-inhibition related effects. Compound 4e with a
p-bromophenyl and 4k with a p-pentylphenyl-substituted 1,2,3-triazole L-ASA both exerted a selective
cytostatic effect on MCF-7 cells (IC50 = 6.72 µM; IC50 = 26.91 µM, respectively). Western blot analysis
of the relative expression of HIF-1α and NOS2 proteins showed that compound 4e strongly increased
the expression of hydroxylated HIF-1α and somewhat decreased the expression of NOS2, indicating its
role in the HIF-1-triggered response of MCF-7 cells to hypoxia. Cellular-metabolism analysis showed
that compound 4e increased the basal respiration and ATP production of MCF-7 cells, while it did
not affect the basal cell respiration and ATP production of HFF-1 cells, which is in agreement with
MTT-results, in which 4e showed no cytotoxicity on HFF-1 cells. Overall, 4-substituted 1,2,3-triazole
L-ASA conjugates were identified as a promising chemical entity that affected the HIF-1α signaling
pathway, and further structure optimization of the saturated C4-C5(OH) derivatives could lead to a
more potent and selective growth-inhibition effect on breast adenocarcinoma (MCF-7) cells.
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